Pharmaceutical composition
By adding specific components to the aqueous composition of hyaluronic acid derivative Dic-HA, the formation and accumulation of diclofenac lactam are inhibited, the problem of short-term efficacy is solved, and the long-term stability and economic preservation of the drug are achieved. use.
Patent Information
- Application Number
- CN201980074798.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2018-11-16
- Filing Date
- 2019-11-15
- Publication Date
- 2024-11-19
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
The prior art cannot effectively inhibit the formation and accumulation of diclofenac lactams in biological organisms by the hyaluronic acid derivative Dic-HA, resulting in a short-term efficacy and lack of technical means to prevent the formation of diclofenac lactams.
The addition of nonionic surfactant, hydroxyalkylated cyclodextrin, C1-C3 monool, C2-C3 diol, C3-C6 triol, and polyalkylene diol to the Dic-HA composition , gamma-lactone, polyvinylpyrrolidone, chlorogenic acids and alkyl sulfates, etc., form an aqueous composition to inhibit the formation and accumulation of diclofenac lactam.
Effective inhibition of diclofenac lactam is achieved, extending the stability and efficacy duration of the drug, and reducing manufacturing and storage costs.
Smart Images

Figure BDA0003063897010000041 
Figure BDA0003063897010000081 
Figure BDA0003063897010000131
Abstract
Description
Technical Field
[0001] The present invention relates to a pharmaceutical composition comprising a hyaluronic acid derivative. Background Art
[0002] Osteoarthritis (hereinafter referred to as "OA" in this specification) is a functional disorder caused by joint pain and joint degeneration, which is the most common joint disease in the world, and is one of the main causes of physical disorders that cause problems in the daily life of the elderly. In addition, similar to OA, rheumatoid arthritis (hereinafter referred to as "RA" in this specification) is known as polyarthritis as a disease with joint swelling and pain. For RA, if the symptoms persist for a long time and the symptoms develop, the cartilage and bone are destroyed and degenerate and deform, resulting in physical disorders such as narrowing the range of joint movement and causing problems in daily life.
[0003] At present, as a medicine for arthritis such as osteoarthritis and rheumatoid arthritis, preparations using hyaluronic acid and its derivatives are used. Hyaluronic acid preparations are usually made into injections, and the purpose is to improve the functional disorders caused by arthritis and suppress pain through the lubrication, impact absorption, cartilage metabolism improvement, etc. of hyaluronic acid, and directly give it to the joints such as the knee and shoulder as the affected part. As a commercialized hyaluronic acid preparation, for example, there are those containing purified sodium hyaluronate as an active ingredient (for example, Artz (registered trademark), Suvenyl (registered trademark)). It is necessary to give the preparation 3 to 5 times continuously at a frequency of once a week.
[0004] In addition, among preparations containing cross-linked hyaluronic acid as an active ingredient, there are known those that are administered three times continuously at a frequency of once a week (for example, Synvisc (registered trademark)) and those that are used for single administration in which treatment is completed with a single administration (for example, Synvisc-One (registered trademark), Gel-One (registered trademark), MONOVISC (registered trademark)).
[0005] On the other hand, steroidal and non-steroidal anti-inflammatory compounds are known to be fast-acting agents and are also used for treatments aimed at relieving joint pain caused by OA and RA. For example, triamcinolone acetonide, a steroid, is used to treat joint diseases such as rheumatoid arthritis. There are commercially available drugs for intra-articular injection, and treatment requires administration every 1 to 2 weeks. In addition, among non-steroidal anti-inflammatory compounds, for example, ointments and oral preparations containing diclofenac sodium as an active ingredient are known to require administration multiple times a day in order to exhibit anti-inflammatory effects.
[0006] It is also known that a mixture or conjugate of hyaluronic acid or its derivatives and steroid or non-steroidal anti-inflammatory compounds are used as active ingredients. For example, a mixture of cross-linked hyaluronic acid and triamcinolone hexaacetone compound (CINGAL (registered trademark)) is commercialized as a reagent for single administration. In addition, it is also known that hyaluronic acid or its derivatives are connected with steroid or non-steroidal anti-inflammatory compounds. For example, patent documents 1 and 2 record derivatives of anti-inflammatory compounds introduced into hyaluronic acid through spacers. These are aimed at both quick-acting pain relief and long-term pain relief by improving functional disorders, but are still in the development stage, and no licensed drugs have been listed so far.
[0007] As another example, with the goal of both relieving pain quickly and relieving long-term pain by improving functional impairment, a conjugate in which diclofenac, an anti-inflammatory compound, is introduced at a certain ratio into the sugar chain of hyaluronic acid (hereinafter sometimes referred to as "Dic-HA") is being developed. However, Dic-HA is also still in the development stage.
[0008] As a stabilization technique for hyaluronic acid, Patent Document 3 discloses a method of adding an iodine-containing reducing agent and / or a sulfur-containing reducing agent to hyaluronic acid. In addition, Patent Document 4 discloses that an aqueous composition containing hyaluronic acid is stabilized by sorbitol.
[0009] Prior art literature
[0010] Patent Literature
[0011] Patent Document 1: International Publication No. 2005 / 066214
[0012] Patent Document 2: International Publication No. 2015 / 005458
[0013] Patent Document 3: Japanese Patent Application Laid-Open No. 10-212303
[0014] Patent Document 4: International Publication No. 2017 / 131130 Summary of the invention
[0015] Diclofenac generated from Dic-HA is a low molecular weight compound, so it is not easy to stay in the administration site (for example, the synovium in the joint), and is transferred to the lymph, blood and other places outside the administration site at an early stage. Therefore, from the viewpoint of long-term persistence of drug efficacy, it is not preferred to generate diclofenac in the pharmaceutical composition before administration to the body. However, the behavior of generating diclofenac from Dic-HA is not clear, and it is not clear whether it is necessary to simply prevent the generation in practice, and if necessary, how to prevent it.
[0016] The present inventors confirmed the presence of decomposition products of Dic-HA in the Dic-HA-containing composition during development. In addition, the decomposition products were analyzed, and it was confirmed that the molecules generated from Dic-HA were contained in the composition not only in the form of diclofenac but also in the form of diclofenac lactam. In addition, it was confirmed that the accumulation amount of diclofenac lactam increased depending on the storage period, heat treatment, etc.
[0017] The present inventors have found that diclofenac itself is a physiologically active substance having an anti-inflammatory effect, but the Cox-2 inhibitory activity of diclofenac lactam, which is its lactam form, is about 1 / 100 of that of diclofenac and is not considered to be a physiologically active anti-inflammatory substance. As a result, the inventors have more clearly found the significance of providing a composition that inhibits the production of physiologically inactive diclofenac lactam and inhibits the accumulation of diclofenac lactam.
[0018] As a stabilization technology of hyaluronic acid, in patent documentation 3, a method of adding an iodine-containing reducing agent and / or a sulfur-containing reducing agent to hyaluronic acid is disclosed, but these reducing agents are used to suppress the molecular weight reduction of hyaluronic acid, and no record or enlightenment is made about suppressing the generation of diclofenac by a hyaluronic acid conjugate. In addition, in patent documentation 4, an aqueous composition comprising hyaluronic acid is disclosed that is stabilized by sorbitol, but as an index here, the viscosity reduction of the aqueous composition is suppressed, and the so-called stabilization is understood as the suppression of the molecular weight reduction of hyaluronic acid. That is, neither disclosure nor enlightenment is made about suppressing the generation of diclofenac components by a hyaluronic acid conjugate such as Dic-HA.
[0019] As described above, although there are reports on stabilization technologies related to the suppression of molecular weight reduction of hyaluronic acid, there is no knowledge on technologies for suppressing the generation of diclofenac lactam due to the decomposition of Dic-HA. The present inventors have found that there are contradictory issues related to decomposition performance, such as suppressing the decomposition of Dic-HA (suppressing the accumulation of diclofenac lactam) before administration to patients as a drug, and desiring to release diclofenac having physiological activity as an anti-inflammatory agent through sustained-release decomposition of Dic-HA in the patient's body after administration, but the current situation is that the existing technology does not provide any solution.
[0020] The present inventors have found that the amount of diclofenac lactam accumulated in a Dic-HA-containing composition can be suppressed by allowing a certain compound to coexist in the Dic-HA-containing composition or by improving the filterability of the Dic-HA-containing aqueous composition.
[0021] One aspect of the present invention relates to a pharmaceutical composition comprising a compound represented by the following formula (1) and a component (A), wherein the component (A) is at least one compound selected from the group consisting of a nonionic surfactant, a hydroxyalkylated cyclodextrin, a C1-C3 monohydric alcohol, a C2-C3 dihydric alcohol, a C3-C6 trihydric alcohol, a polyalkylene glycol, a γ-lactone, a polyvinyl pyrrolidone, chlorogenic acids, and alkyl sulfates, and salts thereof. The pharmaceutical composition can be suitably used as a therapeutic agent for topical administration (e.g., an anti-inflammatory agent, a pain suppressant), and is particularly preferably used as a composition for treating joint diseases such as OA and RA. Another aspect of the present invention relates to a method for producing the pharmaceutical composition, comprising a step of allowing the compound represented by the following formula (1) and the aforementioned component (A) to coexist. Another aspect of the present invention relates to a method for inhibiting the formation of diclofenac lactam from a compound represented by the following formula (1), comprising a step of allowing the compound represented by the following formula (1) and the aforementioned component (A) to coexist. Another aspect of the present invention relates to a method for inhibiting the production of a diclofenac component from a compound represented by the following formula (1), comprising the step of allowing the compound represented by the following formula (1) to coexist with the aforementioned component (A).
[0022] Another aspect of the present invention relates to an aqueous composition comprising a compound represented by the following formula (1), and a maximum treatment volume (V max ) is 1.0g / cm 2 above.
[0023]
[0024] In formula (1), a is greater than or equal to 0.01 and less than or equal to 0.7, a+b is 1, n is an integer greater than or equal to 25 and less than or equal to 25000, the arrangement of each disaccharide structural unit is optionally random or block-like, and in each disaccharide structural unit, R is independently a carboxyl group or a carboxylate group.
[0025] In this specification, the compound represented by the above formula (1) is sometimes referred to as a "hyaluronic acid derivative". In addition, in formula (1), the disaccharide structural unit present at a ratio of a is referred to as a "diclofenac-introduced disaccharide structural unit", and the disaccharide structural unit present at a ratio of b is referred to as a "hyaluronic acid disaccharide structural unit" (i.e., a structure in which N-acetyl-D-glucosamine and D-glucuronic acid or a salt thereof are bonded in β1,3). In addition, there is no particular distinction between the "diclofenac-introduced disaccharide structural unit" and the "hyaluronic acid disaccharide structural unit", and they are also simply referred to as "disaccharide structural unit".
[0026] In this specification, the component (A) and the filterability improver are also collectively referred to as "additive components".
[0027] As more specific examples, the present invention relates to the following [1] to
[23] .
[0028] [1] A pharmaceutical composition comprising a compound represented by formula (1) and component (A), wherein the component (A) is at least one compound selected from the group consisting of a nonionic surfactant, a hydroxyalkylated cyclodextrin, a C1-C3 monohydric alcohol, a C2-C3 dihydric alcohol, a C3-C6 trihydric alcohol, a polyalkylene glycol, a γ-lactone, a polyvinyl pyrrolidone, chlorogenic acids, an alkyl sulfate, and salts thereof.
[0029] [2] The pharmaceutical composition according to the above-mentioned [1], which is used for treating joint diseases.
[0030] [3] A kit comprising a syringe in which the pharmaceutical composition according to [1] or [2] is filled in a syringe barrel.
[0031] [4] A kit comprising a vial and a syringe, wherein the vial contains the pharmaceutical composition described in [1] or [2] above.
[0032] [5] A method for producing a pharmaceutical composition containing a compound represented by formula (1), comprising the step of allowing the compound represented by formula (1) and the aforementioned component (A) to coexist.
[0033] [6] A method for inhibiting the formation of diclofenac lactam from a compound represented by formula (1), comprising the step of allowing the compound represented by formula (1) and the aforementioned component (A) to coexist.
[0034] [7] Use of component (A) in the manufacture of a pharmaceutical composition containing a compound represented by formula (1), comprising a step of allowing the aforementioned component (A) and the aforementioned compound represented by formula (1) to coexist, wherein the aforementioned pharmaceutical composition is used for treating joint diseases, and the aforementioned component (A) is a compound that inhibits the formation of diclofenac lactam from the compound represented by formula (1).
[0035] [8] Component (A) is a component for treating a human joint disease and is used together with the compound represented by formula (1) as a constituent component of a pharmaceutical composition for treating a joint disease.
[0036] [9] A method for treating a human joint disease, comprising administering a pharmaceutical composition to a joint of a patient suffering from the joint disease, wherein the pharmaceutical composition comprises an effective amount of a compound represented by formula (1) and component (A).
[0037]
[10] An aqueous composition comprising a compound represented by formula (1), wherein the maximum treatment volume (V max ) is 1.0g / cm 2 More than one, wherein the aforementioned maximum processing capacity (V max) is the following value: the aqueous composition at a liquid temperature of 70° C. is filtered using a polyvinylidene fluoride filter membrane with a pore size of 0.22 μm under a pressure of 0.6 MPa, and the total filtration volume per unit effective filtration area is measured every 30 seconds until the flow rate is less than 1 / 10 of the flow rate at the start of filtration, and the measured value obtained is applied to the value derived in the following formulas A and B:
[0038] Formula A:
[0039] t / V=at+b
[0040] Formula B:
[0041] V max =1 / a
[0042] In the above formulas A and B, t is the filtration time (minutes), V is the total filtration volume per unit effective filtration area (g / cm 2 ), a is the slope of equation A, and b is the intercept of equation A.
[0043]
[11] The aqueous composition according to
[10] above, further comprising a filterability improving agent.
[0044]
[12] The aqueous composition according to
[11] , wherein the filterability improving agent is selected from the group consisting of polyalkylene glycols, C1-C3 monohydric alcohols, hydroxyalkylated cyclodextrins, and salts thereof.
[0045]
[13] The aqueous composition according to
[11] or
[12] , wherein the relative amount of diclofenac lactam measured under the following conditions is 0.9 or less (e.g., 0.8 or less or 0.75 or less):
[0046] A test composition in which the compound represented by formula (1) and a filterability improver coexisted, and a control composition having the same composition as above except that the filterability improver was not contained, were stored in a thermostatic chamber at 60° C. for 1 week, and then the amounts of diclofenac lactam accumulated in the test composition and the control composition were measured by high performance liquid chromatography, and the relative amount of diclofenac lactam accumulated in the test composition when the amount of diclofenac lactam accumulated in the control composition was set to 1 was calculated.
[0047]
[14] The aqueous composition according to any one of
[11] to
[13] above, wherein the relative amount of diclofenac measured under the following conditions is less than 1 (e.g., less than 0.95 or less than 0.9):
[0048] A test composition in which the compound represented by formula (1) and a filterability improver coexisted, and a control composition having the same composition as above except that the filterability improver was not contained, were stored in a thermostatic chamber at 60° C. for 1 week, and then the amount of diclofenac accumulated in the test composition and the control composition was measured by high performance liquid chromatography, and the relative amount of diclofenac accumulated in the test composition when the amount of diclofenac accumulated in the control composition was set to 1 was calculated.
[0049]
[15] The aqueous composition according to any one of
[10] to
[14] , which is used for treating joint diseases.
[0050]
[16] An aqueous composition according to any one of
[10] to
[15] , comprising the compound represented by formula (1) at a concentration of 0.01 w / v% to 80 w / v%, 0.1 w / v% to 10 w / v%, 0.5 w / v% to 5 w / v% or 1 w / v%.
[0051]
[17] An aqueous composition according to any one of
[11] to
[16] , comprising a filterability improving agent at a concentration of 0.01 w / v% to 60 w / v%, 0.1 w / v% to 30 w / v%, 1 w / v% to 15 w / v%, or 2 w / v% to less than 10 w / v%.
[0052]
[18] An aqueous composition according to any one of
[10] to
[17] , comprising water at a concentration of 10 w / v% to 99.98 w / v%, 60 w / v% to 99.8 w / v%, 80 w / v% to 98.5 w / v%, or greater than 89 w / v% to 97 w / v%.
[0053]
[19] A kit comprising a syringe in which a syringe barrel is filled with the aqueous composition according to any one of
[10] to
[18] .
[0054]
[20] A kit comprising a vial and a syringe, wherein the vial contains the aqueous composition according to any one of
[10] to
[18] .
[0055]
[21] A method for producing a pharmaceutical composition containing a compound represented by formula (1), comprising a step of allowing the compound represented by formula (1) and a filterability improving agent to coexist.
[0056]
[22] A method for improving the filterability of a compound represented by formula (1), comprising a step of allowing the compound represented by formula (1) and a filterability improving agent to coexist.
[0057]
[23] A method for treating a human joint disease, comprising the step of administering the aqueous composition according to any one of
[10] to
[18] above to a joint of a patient suffering from a joint disease. DETAILED DESCRIPTION
[0058] According to the present invention, there is provided a Dic-HA-containing pharmaceutical composition in which the accumulation amount of diclofenac lactam is suppressed.
[0059] Hereinafter, the mode for carrying out the present invention will be described with reference to examples.
[0060] One aspect of the present invention relates to a pharmaceutical composition comprising a compound represented by the following formula (1) and a component (A), wherein the component (A) is at least one compound selected from the group consisting of a nonionic surfactant, a hydroxyalkylated cyclodextrin, a C1-C3 monohydric alcohol, a C2-C3 dihydric alcohol, a C3-C6 trihydric alcohol, a polyalkylene glycol, a γ-lactone, a polyvinyl pyrrolidone, chlorogenic acids, and alkyl sulfates, and salts thereof:
[0061]
[0062] (In formula (1), a is greater than or equal to 0.01 and less than or equal to 0.7, a+b is 1, n is an integer greater than or equal to 25 and less than or equal to 25000, the arrangement of each disaccharide structural unit is optionally random or block-like, and in each disaccharide structural unit, R is independently a carboxyl group or a carboxylate group).
[0063] Another aspect of the present invention is a pharmaceutical composition comprising a compound represented by formula (1) and an additional component, wherein the production and / or accumulation of diclofenac is suppressed.
[0064] Another aspect of the present invention relates to a method for producing a pharmaceutical composition containing a compound represented by formula (1), the method comprising a step of allowing the compound represented by formula (1) to coexist with the following component (A), wherein the component (A) is at least one compound selected from the group consisting of a nonionic surfactant, a hydroxyalkylated cyclodextrin, a C1-C3 monohydric alcohol, a C2-C3 dihydric alcohol, a C3-C6 trihydric alcohol, a polyalkylene glycol, a γ-lactone, a polyvinyl pyrrolidone, chlorogenic acids and alkyl sulfates, and salts thereof.
[0065] Another aspect of the present invention relates to a method for inhibiting the formation of diclofenac lactam from a compound represented by formula (1), the method comprising the step of allowing the compound represented by formula (1) to coexist with at least one selected from the group consisting of a nonionic surfactant, a hydroxyalkylated cyclodextrin, a C1-C3 monohydric alcohol, a C2-C3 dihydric alcohol, a C3-C6 trihydric alcohol, a polyalkylene glycol, a γ-lactone, a polyvinyl pyrrolidone, chlorogenic acids and alkyl sulfates, and salts thereof.
[0066] Another aspect of the present invention relates to the use of at least one substance selected from the group consisting of nonionic surfactants, hydroxyalkylated cyclodextrins, C1-C3 monohydric alcohols, C2-C3 dihydric alcohols, C3-C6 trihydric alcohols, polyalkylene glycols, γ-lactones, polyvinyl pyrrolidone, chlorogenic acids and alkyl sulfates, and salts thereof, in the manufacture of a pharmaceutical composition containing a compound represented by formula (1), wherein the pharmaceutical composition is used for the treatment of joint diseases, and the at least one substance is a compound that inhibits the formation of diclofenac lactam from the compound represented by formula (1).
[0067] Another aspect of the present invention relates to at least one compound for treating human joint diseases, wherein the at least one compound is selected from the group consisting of nonionic surfactants, hydroxyalkylated cyclodextrins, C1-C3 monohydric alcohols, C2-C3 dihydric alcohols, C3-C6 trihydric alcohols, polyalkylene glycols, γ-lactones, polyvinyl pyrrolidone, chlorogenic acids and alkyl sulfates, and salts thereof, and is used together with the compound represented by formula (1) as a constituent component of a pharmaceutical composition for treating joint diseases.
[0068] Another aspect of the present invention relates to a method for treating human joint diseases, comprising the step of administering a pharmaceutical composition to a joint of a patient with a joint disease, wherein the pharmaceutical composition contains an effective amount of a compound represented by formula (1) and at least one compound, wherein the at least one compound is selected from the group consisting of a nonionic surfactant, a hydroxyalkylated cyclodextrin, a C1-C3 monohydric alcohol, a C2-C3 dihydric alcohol, a C3-C6 trihydric alcohol, a polyalkylene glycol, γ-lactone, polyvinyl pyrrolidone, chlorogenic acids and alkyl sulfates, and salts thereof, and wherein the compound represented by formula (1) is inhibited from generating a diclofenac component.
[0069] Another aspect of the present invention relates to a method for preserving a pharmaceutical composition, which is a method for preserving a compound represented by formula (1), wherein the pharmaceutical composition is a pharmaceutical composition in which the production and / or accumulation of diclofenac lactam is suppressed during storage, and comprises a compound selected from the group consisting of a nonionic surfactant, a hydroxyalkylated cyclodextrin, a C1-C3 monohydric alcohol, a C2-C3 dihydric alcohol, a C3-C6 trihydric alcohol, a polyalkylene glycol, a γ-lactone, a polyvinyl pyrrolidone, chlorogenic acids and alkyl sulfates, and salts thereof.
[0070] Another aspect of the present invention relates to a kit comprising a pharmaceutical composition and a syringe, wherein the pharmaceutical composition contains a compound represented by formula (1) and at least one compound; the at least one compound is selected from the group consisting of a nonionic surfactant, a hydroxyalkylated cyclodextrin, a C1-C3 monohydric alcohol, a C2-C3 dihydric alcohol, a C3-C6 trihydric alcohol, a polyalkylene glycol, γ-lactone, polyvinyl pyrrolidone, chlorogenic acids and alkyl sulfates, and salts thereof, and inhibits the generation of a diclofenac component from the compound represented by formula (1).
[0071] According to one aspect of the present invention, in a pharmaceutical composition containing a compound represented by formula (1), by allowing at least one compound selected from the group consisting of a nonionic surfactant, a hydroxyalkylated cyclodextrin, a C1-C3 monohydric alcohol, a C2-C3 dihydric alcohol, a C3-C6 trihydric alcohol, a polyalkylene glycol, a γ-lactone, a polyvinyl pyrrolidone, chlorogenic acids, and an alkyl sulfate, and salts thereof to coexist, it is possible to inhibit the accumulation of diclofenac lactam generated from the compound represented by formula (1) during storage of the pharmaceutical composition.
[0072] According to one aspect of the present invention, in a pharmaceutical composition containing a compound represented by formula (1), by allowing at least one compound selected from the group consisting of a nonionic surfactant, a hydroxyalkylated cyclodextrin, a C1-C3 monohydric alcohol, a C2-C3 dihydric alcohol, a γ-lactone, a polyvinyl pyrrolidone, chlorogenic acids and alkyl sulfates, and salts thereof to coexist, it is possible to inhibit the accumulation of diclofenac generated from the compound represented by formula (1) during storage of the pharmaceutical composition.
[0073] According to one aspect of the present invention, a pharmaceutical composition having excellent long-term stability and a prolonged shelf life is provided. The pharmaceutical composition can be stored in a container (e.g., a vial, a syringe, etc.) in the form of an aqueous composition for injection, and the accumulation of diclofenac lactam over time during storage can be suppressed. As a result, the pharmaceutical composition can be efficiently supplied, and the cost of manufacturing / storage can be reduced, which is good news for patients who need the pharmaceutical composition.
[0074] In this specification, "carboxylate group" refers to a structure in which a carboxylate [-C(=O)-O-] forms a salt with a cation, and may be in the form of a pharmaceutically acceptable salt. The cation forming the carboxylate is not particularly limited as long as it can form a salt with the carboxylate [-C(=O)-O-], and examples thereof include sodium ions, potassium ions, calcium ions, magnesium ions, and the like. In a preferred embodiment, the carboxylate group is represented by -CO2Na (i.e., the cation is a sodium ion).
[0075] In this specification, "pharmaceutically acceptable salts" can be exemplified by metal salts such as sodium salts, potassium salts, calcium salts, magnesium salts, and barium salts; ammonium salts; amine salts such as methylamine salts, diethylamine salts, ethylenediamine salts, cyclohexylamine salts, and ethanolamine salts; inorganic acid salts such as hydrochlorides, sulfates, hydrogen sulfates, nitrates, phosphates, hydrobromides, and hydroiodides; organic acid salts such as acetates, phthalates, fumarates, maleates, oxalates, succinates, methanesulfonates, p-toluenesulfonates, tartrates, bitartrates, and malates, but are not limited to these.
[0076] In the present specification, "diclofenac component" is used as a general term for diclofenac and diclofenac lactam. The amount of diclofenac component can be measured by a method using high performance liquid chromatography (HPLC) described in Examples.
[0077] In the present specification, component (A) is at least one compound selected from the group consisting of nonionic surfactants, hydroxyalkylated cyclodextrins, C1-C3 monohydric alcohols, C2-C3 dihydric alcohols, C3-C6 trihydric alcohols, polyalkylene glycols, γ-lactones, polyvinyl pyrrolidone, chlorogenic acids, alkyl sulfates, and salts thereof. Provided is a pharmaceutical composition containing component (A) to inhibit the production and / or accumulation of diclofenac lactam.
[0078] In this specification, "coexistence" means that the target substances are in a state where they can contact each other. For example, it can be carried out by adding component (A) to the compound represented by formula (1), or by adding the compound represented by formula (1) to component (A). In addition, it can also be carried out by mixing the compound represented by formula (1) with component (A).
[0079] The salt used as the component (A) is not particularly limited, similarly to the above-mentioned "pharmaceutically acceptable salt", and examples thereof include the pharmaceutically acceptable salts described above.
[0080] In one embodiment, component (A), for example, in a composition containing a compound represented by formula (1), has a function of inhibiting the accumulation and / or production of diclofenac lactam.
[0081] In a preferred embodiment, component (A) is used in the composition comprising the compound represented by formula (1) as a component that further inhibits the accumulation and / or production of diclofenac.
[0082] In the present specification, "inhibition" of the production and accumulation of a diclofenac component means reducing the amount of production and / or accumulation of the diclofenac component.
[0083] The accumulation and / or generation of the diclofenac component can be determined by storing an aqueous composition containing the compound represented by formula (1) and component (A) in a thermostatic chamber at 60° C. for one week and then measuring the amount of the diclofenac component accumulated in the aqueous composition. The accumulation inhibition effect and / or generation inhibition effect of the diclofenac component brought about by component (A) can be evaluated by storing an aqueous composition of the same composition under the same conditions except that component (A) is not included, and calculating the amount of the diclofenac component in the test aqueous composition as a relative amount when the amount of the diclofenac component accumulated in the aqueous composition is set to 1 (when the relative amount is less than 1, the accumulation and / or generation of the diclofenac component is suppressed). By this method, it can be determined whether the aqueous composition containing the compound represented by formula (1) suppresses the accumulation and / or generation of the diclofenac component.
[0084] The relative amount of diclofenac lactam calculated under the above conditions is preferably 0.9 or less, more preferably 0.8 or less, and further preferably 0.75 or less. In addition, the relative amount of diclofenac calculated under the above conditions is preferably less than 1, more preferably 0.95 or less, and further preferably 0.9 or less.
[0085] The composition may contain one kind of component (A) alone or two or more kinds thereof.
[0086] When two or more components (A) are included, the combination is not particularly limited, and examples thereof include a combination of two components (A) such as a polyalkylene glycol and a nonionic surfactant, or a polyalkylene glycol and a hydroxyalkylated cyclodextrin; or a combination of three components (A) such as a polyalkylene glycol, a nonionic surfactant, and a hydroxyalkylated cyclodextrin. As described in the Examples below, by allowing a plurality of components (A) to coexist, a higher inhibitory effect of the diclofenac component can be expected.
[0087] Another aspect of the present invention is an aqueous composition in which a compound represented by formula (1) and a component that inhibits the accumulation and / or production of a diclofenac component coexist, wherein the relative amount of diclofenac lactam after storage in a thermostatic chamber at 60° C. for one week is 0.9 or less, and more preferably 0.75 or less. The relative amount is a value obtained when the amount of diclofenac lactam accumulated in the control composition is set to 1 when the same aqueous composition (control composition) is stored under the same conditions except that the component that inhibits the accumulation and / or production of a diclofenac component is not contained.
[0088] The present inventors have found that component (A) can also be used as a diclofenac component production inhibitor, a diclofenac lactam accumulation inhibitor in the composition, or a filterability improving agent for an aqueous composition containing a compound represented by formula (1) as described below.
[0089] In one embodiment, the composition contains component (A) at a ratio of 0.01 w / v% to 60 w / v%, preferably 0.1 w / v% to 30 w / v%, more preferably 1 w / v% to 15 w / v%, particularly preferably 2 w / v% to less than 10 w / v%.
[0090] Here, diclofenac has a structure represented by the following formula (2), and diclofenac lactam has a structure represented by the following formula (3).
[0091]
[0092] In the present specification, the "nonionic surfactant" is a nonionic surfactant generally understood by those skilled in the art.
[0093] Non-limiting examples of nonionic surfactants include polysorbates (polysorbate 20, polysorbate 60, polysorbate 80, etc.), alkylphenol polyoxyethylene ethers (octylphenol polyoxyethylene ether (Triton (trademark) X-100), nonylphenol polyoxyethylene ether, etc.), alkyl glucosides (decyl glucoside, lauryl glucoside, octyl glucoside, etc.), polyoxyethylene glycol ethers (octaethylene glycol monododecyl ether, pentaethylene glycol monododecyl ether, etc.), ether, polyoxyethylene lauryl ether, polyoxyethylene hexadecyl ether, etc.), polyoxyethylene glycol alkylphenol ether (polyoxyethylene glycol octylphenol ether, polyoxyethylene glycol nonylphenol ether, etc.), polyoxyethylene lauryl ether, polyoxypropylene glycol alkyl ether, glycerol alkyl ester, polyoxyethylene glycol sorbitan alkyl ester, monodecanoyl sucrose, cocamide, dodecyl dimethylamine oxide, and alkoxylated alcohols (ethoxylated alcohol, propoxylated alcohol, ethoxylated propoxylated alcohol, etc.), and pharmaceutically acceptable salts thereof.
[0094] In one embodiment, polysorbate 20, polysorbate 80, Triton X-100, octyl glucoside, and pharmaceutically acceptable salts thereof are used as preferred nonionic surfactants.
[0095] In the present specification, "hydroxyalkylated cyclodextrin" refers to hydroxyalkylated cyclodextrin commonly understood by those skilled in the art.
[0096] Non-limiting examples of hydroxyalkylated cyclodextrins include hydroxyethyl-β-cyclodextrin (HE-β-CD) and hydroxypropyl-β-cyclodextrin (HP-β-CD). In one embodiment, HE-β-CD and HP-β-CD are used as preferred hydroxyalkylated cyclodextrins.
[0097] In the present specification, "C1 to C3 monohydric alcohol" refers to a monohydric alcohol having 1 to 3 carbon atoms, such as methanol, ethanol, n-propanol, and isopropanol.
[0098] In one embodiment, ethanol is used as a preferred C1 to C3 monohydric alcohol.
[0099] In the present specification, "C2-C3 diol" refers to a diol having 2 to 3 carbon atoms, such as 1,2-ethylene glycol and propylene glycol.
[0100] In one embodiment, propylene glycol is used as a preferred C2-C3 diol.
[0101] In the present specification, the "C3-C6 triol" refers to a triol having 3 to 6 carbon atoms, such as glycerol, 1,2,3-butanetriol, and D-glucal.
[0102] In one embodiment, glycerol, 1,2,3-butanetriol, and D-glucal are each used as a preferred C3 to C6 triol.
[0103] In this specification, "polyalkylene glycol" refers to a polymer of alkylene glycol such as polyethylene glycol and polypropylene glycol. Non-limiting examples of polyethylene glycol include PEG100 to 10000 (e.g., PEG200, PEG300, PEG400, PEG500, PEG600, PEG4000, and PEG6000). These examples are all used as preferred polyalkylene glycols in one embodiment of the present invention.
[0104] In a preferred embodiment, polyethylene glycol having a weight average molecular weight of 200 or more and 6000 or less can be used.
[0105] In a more preferred embodiment, polyethylene glycol having a weight average molecular weight of 400 to 6000 can be used.
[0106] In the present specification, "γ-lactone" is a lactone having a 5-membered ring, which is generally understood by those skilled in the art.
[0107] Non-limiting examples of γ-lactone include D-erythrolactone, sodium erythorbate, ascorbic acid, glucuronolactone, and pharmaceutically acceptable salts thereof.
[0108] In one embodiment, D-erythroleucone lactone, sodium erythorbate, glucuronolactone, and pharmaceutically acceptable salts thereof are used as preferred γ-lactones.
[0109] In the present specification, the "chlorogenic acid" refers to chlorogenic acid or similar compounds such as chlorogenic acid, feruloylquinic acid, dicaffeoylquinic acid, and pharmaceutically acceptable salts thereof.
[0110] In one embodiment, chlorogenic acid and pharmaceutically acceptable salts thereof are used as preferred chlorogenic acids.
[0111] In the present specification, "alkyl sulfate" refers to a sulfate having an octyl group, a nonyl group, a decyl group, a dodecyl group or the like as an alkyl group, and a pharmaceutically acceptable salt thereof.
[0112] As a typical alkyl sulfate ester, sodium dodecyl sulfate (SDS) can be mentioned.
[0113] In one embodiment, SDS is used as a preferred alkyl sulfate.
[0114] From the viewpoint of inhibiting the production and / or accumulation of diclofenac in the composition, in a preferred embodiment, component (A) can use at least one compound selected from the group consisting of nonionic surfactants, hydroxyalkylated cyclodextrins, C1-C3 monohydric alcohols, C2-C3 dihydric alcohols, γ-lactones, polyvinyl pyrrolidone, chlorogenic acids, alkyl sulfates, and salts thereof.
[0115] From the viewpoint of excellent filterability of the composition, in a preferred embodiment, as component (A), a compound selected from the group consisting of polyalkylene glycols, C1 to C3 monohydric alcohols, hydroxyalkylated cyclodextrins, and salts thereof can be used.
[0116] In the present invention, the pharmaceutical composition is preferably used to treat human joint diseases. In this specification, "joint disease" refers to various joint diseases such as knee joint, shoulder joint, cervical joint, hip joint, spinal joint, jaw joint, finger joint, elbow joint, wrist joint, ankle joint, etc. As joint diseases, more specifically, osteoarthritis, rheumatoid arthritis, articular cartilage damage, knee osteonecrosis, femoral osteonecrosis, shoulder arthritis, bacterial arthritis, viral arthritis, neuropathic arthritis, etc. can be exemplified. The composition for treating joint diseases of the present invention is preferably used for osteoarthritis or rheumatoid arthritis, and is more preferably used for osteoarthritis.
[0117] In this specification, "treatment" may refer to the treatment of the disease itself (for example, treatment that cures or improves the organic lesions in the disease), or the treatment of various symptoms associated with the disease (for example, caused by pain, stiffness, joint function (for example, which can be evaluated by the difficulty of daily activities (represented by going up and down stairs, getting on and off a car, etc.)) and the reduction of ADL in the joints). In addition, "treatment" includes not only complete cure, but also improvement of part or all of the symptoms of the disease, and inhibition of disease progression (including maintenance and reduction of the rate of progression) and prevention. Prevention here includes: for example, when organic lesions are observed in the joints, various symptoms associated with joint diseases such as joint function disorders, pain and / or stiffness are not produced, the occurrence of these various symptoms is prevented before they occur. In addition, prevention includes: for example, when no clear organic lesions are observed in the joints, but various symptoms associated with joint diseases such as joint function disorders, pain and / or stiffness are produced, the occurrence of these organic lesions is prevented before they occur, and the development of symptoms that are not significant among these various symptoms is inhibited. The composition is preferably used to improve, cure or inhibit the aggravation of joint diseases, and more preferably to improve or cure symptoms. In one embodiment, the composition can be suitably used to improve, cure or inhibit the aggravation of joint pain, or to improve joint function.
[0118] In this specification, "effective amount" refers to the amount of sufficient ingredients that can obtain the desired response in accordance with a reasonable risk / benefit ratio without excessive harmful side effects (toxicity, irritation and allergic reactions, etc.). This "effective amount" can vary according to various factors such as the symptoms, physique, age, and sex of the patient who is the subject of administration. However, as long as one skilled in the art does not need to conduct each test on the combination of various factors, the effective amount in other cases can be determined based on the results of one or more specific test examples and technical common sense.
[0119] Hyaluronic acid includes a glycosaminoglycan consisting of a basic skeleton obtained by repeating β1,4 bonds and a structure obtained by bonding N-acetyl-D-glucosamine and D-glucuronic acid or its salt by β1,3 as a disaccharide unit (hyaluronic acid disaccharide structural unit), and the hyaluronic acid disaccharide structural unit is a glycosaminoglycan consisting of the basic skeleton. In addition, hyaluronic acid can be obtained by any method using a synthetic product such as a purified product derived from an animal or microorganism, a chemical synthesis, etc.
[0120] The mass average molecular weight of hyaluronic acid and the compound represented by formula (1) is not particularly limited, and examples thereof include 10,000 or more and 10,000,000 or less, preferably 500,000 or more and 5,000,000 or less, more preferably 600,000 or more and 3,000,000 or less, and further preferably 600,000 or more and 1,200,000 or less. It should be noted that in this specification, the "mass average molecular weight" of hyaluronic acid and the compound represented by formula (1) is a value measured by an intrinsic viscosity method, which has the same meaning as the "weight average molecular weight" of these compounds.
[0121] Hyaluronic acid and the compound represented by formula (1) may be in a state of not forming a salt or in a state of forming a salt. Examples of the salt include the pharmaceutically acceptable salts described above.
[0122] The compound represented by formula (1) can be obtained by covalently bonding diclofenac to hyaluronic acid using a compound such as 2-bromoethylamine hydrobromide or 2-aminoethanol as a spacer.
[0123] In the compound represented by formula (1), diclofenac is linked to the spacer through an ester bond, and the spacer is linked to hyaluronic acid through an amide bond.
[0124] In the compound represented by formula (1), each disaccharide structural unit may be randomly or block-linked at a ratio of a to b. That is, the diclofenac-introduced disaccharide structural unit and the hyaluronic acid disaccharide structural unit are randomly or block-linked via β1,4 bonds.
[0125] The terminal of the compound represented by formula (1) is a hydrogen atom or a hydroxyl group.
[0126] In formula (1), a is the ratio of the number of diclofenac disaccharide structural units introduced to the total number of disaccharide structural units, b is the ratio of the number of hyaluronic acid disaccharide structural units to the total number of disaccharide structural units, and a+b is 1. When the ratio shown as a in formula (1) is expressed as a molar fraction, the value of the molar fraction is referred to as the "introduction rate" in this specification. In formula (1), a is 0.01 to 0.7 (as an introduction rate, it is 1 mol% to 70 mol%, and b is 0.3 to 0.99), preferably 0.1 to 0.2 (10 mol% to 20 mol%, and b is 0.8 to 0.9).
[0127] The value of a, the introduction rate, in the formula (1) can be adjusted by changing the reaction equivalents of the condensing agent, the condensation auxiliary agent, the spacer compound, the reaction equivalent of diclofenac, etc. in the reaction step of introducing diclofenac into hyaluronic acid.
[0128] Here, the "introduction rate" in this specification is a value calculated by the following formula 1, and can be obtained by measuring the absorbance.
[0129] Formula 1:
[0130] Introduction rate (mol%) = (number of diclofenac introduced disaccharide structural units / total number of disaccharide structural units) × 100
[0131] More specifically, the introduction rate can be calculated according to the above formula by measuring the absorbance specific to diclofenac using the carbazole absorbance method and using a previously prepared calibration curve of diclofenac.
[0132] In the compound represented by formula (1), n represents the number of all disaccharide structural units and can be calculated by the following formula 2 or 3.
[0133] When n is determined based on the mass average molecular weight of the raw material hyaluronic acid, it can be calculated according to the following formula 2.
[0134] Formula 2:
[0135] n = (mass average molecular weight of hyaluronic acid / mass average molecular weight of disaccharide structural unit)
[0136] When n is determined based on the mass average molecular weight of the compound represented by formula (1) and a and b in formula (1), it can be calculated according to the following formula 3.
[0137] Formula 3:
[0138] n=(mass average molecular weight of the compound represented by formula (1)) / ((mass average molecular weight of diclofenac-introduced disaccharide structural unit×a)+(mass average molecular weight of hyaluronic acid disaccharide structural unit×b))
[0139] n is an integer of 25 to 25000, preferably an integer of 1250 to 12500, more preferably an integer of 1500 to 7500, and further preferably an integer of 1500 to 3000.
[0140] The method of introducing a spacer and diclofenac into hyaluronic acid can be that diclofenac is introduced into hyaluronic acid into which a spacer has been introduced, or diclofenac into which a spacer has been introduced in advance is reacted with hyaluronic acid. For example, by referring to Patent Document 1, Patent Document 2, etc., those skilled in the art can appropriately implement the method.
[0141] In one embodiment, the composition contains the compound represented by formula (1) at a concentration of 0.01 w / v% to 80 w / v%. In a preferred embodiment, the composition contains the compound represented by formula (1) at a concentration of 0.1 w / v% to 10 w / v%, more preferably 0.5 w / v% to 5 w / v%, and particularly preferably 1 w / v%.
[0142] The composition may contain a pharmaceutically acceptable carrier in addition to the compound represented by formula (1). As the pharmaceutically acceptable carrier, aqueous solvents such as water for injection, physiological saline, and Ringer's solution can be preferably exemplified. In one embodiment, the pharmaceutical composition is an aqueous composition. In one embodiment, the composition is prepared by mixing the pharmaceutically acceptable carrier with the compound represented by formula (1). As needed, additives such as buffers may also be added to the composition. In addition, for the composition, after mixing the components, dust removal, sterilization, sterilization, etc. may be performed by, for example, filtering with a filter.
[0143] When compositions such as pharmaceutical compositions are usually used in organisms (mammals, particularly preferably humans), dust removal and sterilization are required. In the case of aqueous compositions, from the perspective of the stability and simplicity of the components, dust removal and sterilization steps are preferably performed by filtration. When the composition is sterilized by filtration through a filter, commercially available membrane filters, sterilized containers, sterilized syringes / syringes, etc. can be used appropriately. For example, as a membrane filter, a membrane filter with a pore size of 0.22 μm can be used. The aqueous composition comprising the compound shown in formula (1) has high viscosity, so according to an embodiment, due to low filterability, there is a worry that it is difficult to prepare an aqueous composition, especially when filtration is sterilized.
[0144] Here, the filterability of the aqueous composition containing the compound represented by formula (1) is poor. Patent document 1 discloses that by subjecting a solution containing Dic-HA to alkaline treatment, a transparent solution having filter filterability can be obtained. However, the inventors conducted a study and found that when the aqueous composition containing Dic-HA is subjected to alkaline treatment, the production of the diclofenac component is promoted. On the other hand, it is found that when the aqueous composition containing the compound represented by formula (1) is sterilized by heat sterilization instead of filter sterilization, the production of the diclofenac component is still promoted.
[0145] One aspect of the present invention relates to an aqueous composition comprising a compound represented by formula (1), wherein the maximum treatment capacity (V max ) means 1.0g / cm 2 According to the above-mentioned aqueous composition, since filtration can be performed, the generation of the diclofenac component in the dust removal and sterilization steps can be prevented / suppressed.
[0146] Maximum processing capacity (V max ) is calculated more specifically as follows. That is, the aqueous composition at a liquid temperature of 70°C is filtered under a pressure of 0.6 MPa using a polyvinylidene fluoride filter membrane with a pore size of 0.22 μm. In this case, the total filtration volume (V) per unit effective filtration area of the filter membrane is measured every 30 seconds until the flow rate (Q) is less than 1 / 10 of the flow rate at the beginning of filtration. The horizontal axis is the filtration time (t), and the vertical axis is t / V. The measurement results are plotted, and the following formula A is calculated within the range of measurement points where the transition of t / V is stable. Maximum processing capacity (V max ) is obtained from the inverse of the slope a of formula A (ie, the following formula B). It should be noted that the flow rate (Q) is the amount of filtration per unit time (ie, Q = dV / dt).
[0147] Formula A:
[0148] t / V=at+b
[0149] Formula B:
[0150] V max =1 / a
[0151] In the above formulas A and B, t is the filtration time (minutes), V is the total filtration volume per unit effective filtration area (g / cm 2 ), a is the slope of equation A, and b is the intercept of equation A.
[0152] Maximum processing capacity (V max ) is larger (i.e., the higher the filterability of the filter is), the less likely the filter will be clogged and the less time required for filtration.
[0153] It should be noted that V max It is an evaluation index used to select filters and optimize them (refer to Kobayashi Kimihiko's "V max "Selection and Optimization Method of Test Filters" "Selection and Optimization Method of Vmax Test Filters", Bioprocess Technical Sheet Basic Technology No. 2, Japan Millipore, August 1997).
[0154] Containing the compound represented by formula (1) and the maximum treatment amount (V max ) is 1.0g / cm 2 The above aqueous composition is useful as a pharmaceutical composition or an intermediate thereof. max ) is preferably 6.0 g / cm 2 More preferably 8.0 g / cm 2 Above, preferably 10 g / cm2 More preferably, 15 g / cm 2 Above, particularly preferably 20 g / cm 2 Maximum processing capacity (V max ) has no particular upper limit, and is, for example, 2000 g / cm 2 Below (1500g / cm 2 Below, 1200g / cm 2 Below, 1000g / cm 2 Below, 800g / cm 2 Below, 500g / cm 2 Below, 200g / cm 2 For example, it may be 1.0 g / cm 2 Above and 2000g / cm 2 Below, 6.0g / cm 2 Above and 1500g / cm 2 Below, 8.0g / cm 2 Above and 1000g / cm 2 Below, 10g / cm 2 Above and 800g / cm 2 Below, 15g / cm 2 Above and 500g / cm 2 Below or 15g / cm 2 Above and 200g / cm 2 the following.
[0155] In one embodiment, the aqueous composition further comprises a filterability improver. In the present invention, a "filterability improver" is a filterability improver that improves the filterability, i.e., the maximum throughput (V) of the aqueous composition comprising the compound represented by formula (1). max ) is not particularly limited. Specific examples of the filterability improver include, for example, the above-mentioned component (A), but are not limited to these.
[0156] In one embodiment, the filterability improving agent is selected from the group consisting of the above-mentioned polyalkylene glycols, C1 to C3 monohydric alcohols, and hydroxyalkylated cyclodextrins.
[0157] From the viewpoint of filterability, in a preferred embodiment, PEG 200 to 6000, methanol, ethanol, n-propanol, isopropanol, hydroxyethyl-β-cyclodextrin, and hydroxypropyl-β-cyclodextrin are used as filterability improving agents.
[0158] In a more preferred embodiment, a compound selected from the group consisting of PEG400, PEG4000, ethanol and hydroxypropyl-β-cyclodextrin can be used in the composition as a filterability improving agent.
[0159] As one embodiment, when PEG400 is contained, it can be particularly preferably used as a filterability improving agent from the viewpoint of significantly improving filterability.
[0160] The aqueous composition may contain one filterability improving agent alone or may contain two or more.
[0161] In one embodiment, the aqueous composition may contain a filterability improving agent at a ratio of 0.01 w / v% to 60 w / v%, preferably 0.1 w / v% to 30 w / v%, more preferably 1 w / v% to 15 w / v%, particularly preferably 2 w / v% to less than 10 w / v%.
[0162] In this specification, an "aqueous composition" is a composition containing 10 w / v% or more and 99.98 w / v% or less of water. The aqueous composition may also be in the form of a solution, a suspension or a gel. Examples of water used to prepare the aqueous composition include water for injection, purified water, distilled water, and the like. The water content in the aqueous composition is preferably 60 w / v% or more and 99.8 w / v% or less, more preferably 80 w / v% or more and 98.5 w / v% or less, and particularly preferably more than 89 w / v% and 97 w / v% or less.
[0163] In one embodiment, the maximum treatment capacity (V max ) is 1.0g / cm 2 In a preferred embodiment, the maximum treatment volume (V) of the aqueous composition containing the compound represented by formula (1) is max ) is 6.0g / cm 2 In a more preferred embodiment, the maximum treatment volume (V) of the aqueous composition containing the compound represented by formula (1) is max ) is 8.0g / cm 2 The relative amount of diclofenac lactam is 0.75 or less. It should be noted that the relative amount of diclofenac lactam is calculated as follows: a test composition in which the compound represented by formula (1) and a filterability improver coexist, and a control composition having the same composition as above except that the filterability improver is not contained, are stored in a thermostatic bath at 60° C. for 1 week, and the amount of diclofenac lactam accumulated in the test composition and the control composition is measured by high performance liquid chromatography, and the relative amount is calculated when the amount of diclofenac lactam accumulated in the control composition is set to 1.
[0164] The buffer that can be included in the composition can be any known buffer to those skilled in the art. Non-limiting examples include citrate buffer, acetate buffer, and phosphate buffer.
[0165] In one embodiment, the citric acid buffer may include a citric acid buffer having a final concentration of 0.1 mM to 500 mM (e.g., 1 mM to 50 mM). Here, the citric acid buffer is preferably adjusted to pH 4.5 to 5.5. As an example of a more preferred pH of the citric acid buffer, pH 4.8 to pH 5.4 can be cited, and as a further example, pH 5.1.
[0166] In one embodiment, the acetate buffer may include an acetate buffer having a final concentration of 0.1 mM to 500 mM (e.g., 1 mM to 50 mM). Here, the acetate buffer is preferably adjusted to pH 4.5 to 5.5. As an example of a more preferred pH of the acetate buffer, pH 4.8 to pH 5.4 can be cited, and as a further example, pH 5.1.
[0167] In one embodiment, the phosphate buffer may include a phosphate buffer having a final concentration of 0.1 mM to 500 mM (e.g., 1 mM to 50 mM). Here, the phosphate buffer is preferably adjusted to pH 6.0 to 7.0. As an example of a more preferred pH of the phosphate buffer, pH 6.3 to pH 6.8 can be cited, and as a further example, pH 6.5.
[0168] In one embodiment, the citric acid buffer can be used in combination with one or more selected from the group consisting of C3-C6 triols, polyalkylene glycols, alkyl sulfates, nonionic surfactants, C1-C3 monools, γ-lactones, chlorogenic acid, C2-C3 diols and polyvinyl pyrrolidone, and salts thereof as component (A).
[0169] In one embodiment, the acetate buffer may be used in combination with one or more selected from the group consisting of hydroxyalkylated cyclodextrin, polyalkylene glycol, C1-C3 monohydric alcohol, nonionic surfactant, polyvinyl pyrrolidone, and salts thereof as component (A).
[0170] In one embodiment, the phosphate buffer may be used in combination with one or more selected from the group consisting of γ-lactone, polyalkylene glycol, C3-C6 triol, and salts thereof as component (A).
[0171] In one embodiment, the composition is prepared by the following steps.
[0172] (Step 1) Predetermined amounts of citric acid hydrate, disodium citrate hydrate, and PEG400 are dissolved in water for injection (WFI).
[0173] (Step 2) A predetermined amount of the compound represented by formula (1) (introduction rate: 18 mol%) was dissolved in the solution of step 1. The dissolved solution was heated to 70°C and degassed by heating under reduced pressure.
[0174] (Step 3) The solution in step 2 was sterilized by filtration using a filter having a pore size of 0.22 μm.
[0175] (Step 4) The solution in step 3 was heated at 70°C for deaeration and then cooled to 10°C.
[0176] (Step 5) A predetermined amount is filled into a syringe under sterile conditions.
[0177] Through the above (step 1) to (step 5), a sterilized pharmaceutical composition containing a hyaluronic acid derivative, PEG400 and a citric acid buffer can be prepared. Here, the concentration of each component can be exemplified by a hyaluronic acid derivative; 0.5-5w / v%, PEG400; 3-30w / v%, and a phosphate buffer; 3-30mM (calculated as citric acid), but the concentration of each component in the pharmaceutical composition is not limited to the aforementioned ranges. Needless to say, component (A) is not limited to PEG400, and the buffer is not limited to a citric acid buffer. The composition of the hyaluronic acid derivative and the pore size of the membrane filter are also the same.
[0178] By making the maximum treatment volume (V max ) is 1.0g / cm 2 As described above, the suitability of filtration sterilization using the filter is improved, and thus the generation of diclofenac lactam in the sterilization step can be suppressed.
[0179] The sterilized pharmaceutical composition after preparation can be stored at a low temperature such as 4°C or at room temperature. In order to inhibit the decomposition of the hyaluronic acid derivative, it is desirable to store it at a low temperature such as 4°C. For example, when the accumulation amount of diclofenac lactam of 0.5w / w% is set as a threshold value relative to the amount of hyaluronic acid derivative in the pharmaceutical composition, and when the accumulation amount exceeds the threshold value, it is judged that the quality is not suitable as a drug, as long as the solution composition is suitable, the composition can be stored as it is at a normal temperature (25°C) environment for several months to about 1 year. This storage period can be extended by about 1 month to 3 months by co-presence of component (A), as calculated from the results of the storage test in the following examples (this conversion is based on the premise that the accumulation of diclofenac lactam is suppressed by 10 to 25% by the co-presence of component (A). This suppression ratio is a level that can be fully achieved, for example, as shown in Example 1 (the results of (1-2)) described later). If the storage period of a pharmaceutical composition with a shelf life of several months of acceptable quality can be extended by more than 1 to 3 months, it is clear that the cost can be reduced, the burden on patients can be alleviated, and a contribution to the medical economy can be achieved. In addition, the sterilized pharmaceutical composition after preparation is more preferably stored under light-shielding conditions. Examples of such conditions include storing the sterilized pharmaceutical composition in a packaged state in a refrigerator or the like.
[0180] The frequency of administration of the pharmaceutical composition can be appropriately adjusted according to the patient's symptoms, etc. From the viewpoint of drug efficacy, for example, a frequency of once a week to once every 52 weeks can be exemplified. As a more preferred example, a frequency of once every 2 weeks to once every 26 weeks or once every 4 weeks to once every 13 weeks can be cited. In the case where sufficient relief can be obtained with one administration, it is of course possible to administer only once. The preferred preparation method of the composition is a solution for injection (e.g., an aqueous composition). For example, when administered to an affected part such as a knee joint in the form of an injection, if the patient's physical burden and mental burden are taken into consideration, a longer dosing interval is desired. In particular, when used as an injection, the solution is preferably colorless and clear.
[0181] In one embodiment, a syringe is provided in which the pharmaceutical composition of the present invention is filled in a syringe. In one embodiment, a set comprising a syringe in which the pharmaceutical composition of the present invention is filled in a syringe can also be provided. The syringe is equipped with a plunger for drug extrusion, etc., which can extrude the composition of the present invention. In one embodiment, the composition filled in the syringe can be provided in a sterilized state. In one embodiment, the syringe can be pre-filled with a single dose of the composition. In addition, the set can be made into a medical injection comprising the following: a solution obtained by dissolving the compound represented by formula (1) in a citric acid buffer, an acetic acid buffer, a phosphate buffer, a physiological saline or water for injection is filled in the syringe, and the solution is sealed in a slidable manner with a plunger for drug extrusion to form a medical injection. The osmotic pressure and viscosity of the solution here can be appropriately adjusted as needed. It should be noted that the plunger for drug extrusion can use a commonly used plunger, which is formed of an elastic body such as rubber or synthetic rubber and inserted into the syringe in a slidable manner in a close-fitting state. In addition, the set can also include a plunger rod, an operating manual or accompanying materials, etc., which is used to press the plunger to extrude the drug. In addition, in one embodiment, the pharmaceutical composition of the present invention can be provided in a vial instead of being filled in a syringe as described above. In this case, the vial is sometimes provided together with a syringe containing a sterilized empty syringe. In addition, it can also be provided in the form of a set including the aforementioned vial and the aforementioned syringe.
[0182] As will be apparent to those skilled in the art, preferred properties and features of one aspect of the present invention may be used independently or in combination with another aspect of the present invention.
[0183] In one embodiment, a pharmaceutical composition is provided that inhibits the production and / or accumulation of diclofenac lactam and the production and / or accumulation of diclofenac is inhibited, and a method for producing the same.
[0184] In one embodiment, a maximum throughput (V max ) shows 1.0g / cm 2 The above-mentioned aqueous composition in which the production of diclofenac lactam is suppressed and its production method.
[0185] In one embodiment, a maximum throughput (V max ) shows 1.0g / cm 2 The above-mentioned aqueous composition in which the production of diclofenac is suppressed and its production method.
[0186] In one embodiment, a maximum throughput (V max ) shows 1.0g / cm 2 The above-mentioned aqueous composition in which the production of diclofenac lactam and the production of diclofenac are suppressed, and a method for producing the same.
[0187] In a specific embodiment, there is provided a pharmaceutical composition in which the production and / or accumulation of diclofenac lactam is suppressed and the production and / or accumulation of diclofenac is suppressed, the pharmaceutical composition comprising a compound represented by formula (1) and at least one compound selected from the group consisting of a nonionic surfactant, a hydroxyalkylated cyclodextrin, a C1-C3 monohydric alcohol, a C2-C3 dihydric alcohol, a γ-lactone, a polyvinyl pyrrolidone, chlorogenic acids and alkyl sulfates, and salts thereof.
[0188] In a specific embodiment, the formation of diclofenac lactam is inhibited, and the maximum processing amount (V max ) shows 1.0g / cm 2 The pharmaceutical composition with improved filterability comprises the compound represented by formula (1) and at least one compound selected from the group consisting of polyalkylene glycol, C1-C3 monohydric alcohol, hydroxyalkylated cyclodextrin, and salts thereof.
[0189] In a specific embodiment, the generation of diclofenac is inhibited, and the maximum treatment amount (V max ) shows 1.0g / cm 2 The pharmaceutical composition with improved filterability comprises the compound represented by formula (1) and at least one compound selected from the group consisting of C1-C3 monohydric alcohols and hydroxyalkylated cyclodextrins, and salts thereof.
[0190] In a specific embodiment, the formation of diclofenac lactam and the formation of diclofenac are inhibited, and the maximum processing amount (V max ) shows 1.0g / cm 2 The pharmaceutical composition with improved filterability comprises the compound represented by formula (1) and at least one compound selected from the group consisting of C1-C3 monohydric alcohols and hydroxyalkylated cyclodextrins, and salts thereof.
[0191] In a specific embodiment, there is provided a method for inhibiting the formation of diclofenac lactam and diclofenac from a compound represented by formula (1), the method comprising the step of allowing the compound represented by formula (1) to coexist with at least one compound selected from the group consisting of a nonionic surfactant, a hydroxyalkylated cyclodextrin, a C1-C3 monohydric alcohol, a C2-C3 dihydric alcohol, a γ-lactone, a polyvinyl pyrrolidone, chlorogenic acids and alkyl sulfates, and salts thereof.
[0192] In a specific embodiment, a method for inhibiting the formation of diclofenac lactam from a compound represented by formula (1) and improving the filterability of the compound represented by formula (1) is provided, the method comprising the step of allowing the compound represented by formula (1) to coexist with at least one compound selected from the group consisting of polyalkylene glycol, C1-C3 monohydric alcohol and hydroxyalkylated cyclodextrin, and salts thereof.
[0193] In a specific embodiment, a method for inhibiting the production of diclofenac from a compound represented by formula (1) and improving the filterability of the compound represented by formula (1) is provided, the method comprising a step of allowing the compound represented by formula (1) to coexist with at least one compound selected from the group consisting of C1 to C3 monohydric alcohols and hydroxyalkylated cyclodextrins, and salts thereof.
[0194] In a specific embodiment, there is provided a method for inhibiting the formation of diclofenac lactam and diclofenac from a compound represented by formula (1), thereby improving the filterability of the compound represented by formula (1), the method comprising the step of allowing the compound represented by formula (1) to coexist with at least one compound selected from the group consisting of C1-C3 monohydric alcohols and hydroxyalkylated cyclodextrins, and salts thereof.
[0195] <Implementation Method>
[0196] Preferred embodiments of the present invention are exemplified below.
[0197] [1] A pharmaceutical composition comprising a compound represented by formula (1) and ingredient (A):
[0198] Component (A): at least one compound selected from the group consisting of nonionic surfactants, hydroxyalkylated cyclodextrins, C1-C3 monohydric alcohols, C2-C3 dihydric alcohols, C3-C6 trihydric alcohols, polyalkylene glycols, γ-lactones, polyvinyl pyrrolidone, chlorogenic acids, alkyl sulfates, and salts thereof,
[0199]
[0200] In formula (1), a is greater than or equal to 0.01 and less than or equal to 0.7, a+b is 1, n is an integer greater than or equal to 25 and less than or equal to 25000, the arrangement of each disaccharide structural unit is optionally random or block-like, and in each disaccharide structural unit, R is independently a carboxyl group or a carboxylate group.
[0201] [2] The pharmaceutical composition according to [1], wherein the component (A) is selected from the group consisting of nonionic surfactants, hydroxyalkylated cyclodextrins, C1-C3 monohydric alcohols and polyalkylene glycols.
[0202] [3] The pharmaceutical composition according to [1] or [2] above, wherein the polyalkylene glycol is polyethylene glycol.
[0203] [4] The pharmaceutical composition according to [3] above, wherein the weight average molecular weight of the polyethylene glycol is 200 or more and 6000 or less.
[0204] [5] The pharmaceutical composition according to any one of [1] to [4], comprising the compound represented by the formula (1) at a concentration of 0.01 w / v% to 80 w / v%, 0.1 w / v% to 10 w / v%, 0.5 w / v% to 5 w / v% or 1 w / v%.
[0205] [6] A pharmaceutical composition according to any one of [1] to [5], wherein the final concentration of the component (A) is 0.01 w / v% to 60 w / v%, 0.01 w / v% to 30 wt%, 1 w / v% to 15 w / v%, or 2 w / v% to less than 10 w / v%.
[0206] [7] The pharmaceutical composition according to any one of [1] to [6], further comprising a buffer selected from the group consisting of a phosphate buffer, a citrate buffer and an acetate buffer.
[0207] [8] The pharmaceutical composition according to any one of [1] to [7] above, wherein the pH is 4.5 to 7.0.
[0208] [9] The pharmaceutical composition according to any one of [1] to [8] above, which is an aqueous composition.
[0209]
[10] The pharmaceutical composition according to any one of [1] to [9] above, which is a pharmaceutical composition for treating joint diseases.
[0210]
[11] The pharmaceutical composition according to
[10] above, wherein the joint disease is osteoarthritis or rheumatoid arthritis.
[0211]
[12] A kit comprising a syringe in which a syringe barrel is filled with the pharmaceutical composition according to any one of [1] to
[11] .
[0212]
[13] A kit comprising a vial and a syringe, wherein the vial contains the pharmaceutical composition according to any one of [1] to
[11] above.
[0213]
[14] A method for producing a pharmaceutical composition, the pharmaceutical composition comprising a compound represented by the following formula (1), the method comprising the step of allowing the compound represented by the following formula (1) to coexist with component (A):
[0214] Component (A): at least one compound selected from the group consisting of nonionic surfactants, hydroxyalkylated cyclodextrins, C1-C3 monohydric alcohols, C2-C3 dihydric alcohols, C3-C6 trihydric alcohols, polyalkylene glycols, γ-lactones, polyvinyl pyrrolidone, chlorogenic acids, alkyl sulfates, and salts thereof,
[0215]
[0216] In formula (1), a is greater than or equal to 0.01 and less than or equal to 0.7, a+b is 1, n is an integer greater than or equal to 25 and less than or equal to 25000, the connection of each disaccharide structural unit is optionally random or block-like, and R in each disaccharide structural unit is independently a carboxyl group or a carboxylate group.
[0217]
[15] The method according to
[14] , wherein the component (A) is selected from the group consisting of a nonionic surfactant, a hydroxyalkylated cyclodextrin, a C1-C3 monohydric alcohol, and a polyalkylene glycol.
[0218]
[16] The method according to
[14] or
[15] above, wherein the polyalkylene glycol is polyethylene glycol.
[0219]
[17] The method according to
[16] above, wherein the weight average molecular weight of the polyethylene glycol is 200 or more and 6000 or less.
[0220]
[18] The method according to any one of
[14] to
[17] , wherein the compound represented by the formula (1) is added at a final concentration of 0.01 w / v% to 80 w / v%, 0.1 w / v% to 10 w / v%, 0.5 w / v% to 5 w / v% or 1 w / v%.
[0221]
[19] The method according to any one of
[14] to
[18] , wherein the component (A) is added to a final concentration of 0.01 w / v% to 60 w / v%, 0.01 w / v% to 30 wt%, 1 w / v% to 15 w / v%, or 2 w / v% to less than 10 w / v%.
[0222]
[20] The method according to any one of
[14] to
[19] , wherein the compound represented by formula (1) and / or component (A) comprises a buffer selected from the group consisting of a phosphate buffer, a citrate buffer and an acetate buffer.
[0223]
[21] The method according to any one of
[14] to
[20] above, wherein the pH of the pharmaceutical composition is 4.5 to 7.0.
[0224]
[22] The method according to any one of
[14] to
[21] above, wherein the pharmaceutical composition is an aqueous composition.
[0225]
[23] A method for inhibiting the formation of diclofenac lactam from a compound represented by the following formula (1), comprising the step of allowing the compound represented by the following formula (1) to coexist with component (A):
[0226] Component (A): at least one compound selected from the group consisting of nonionic surfactants, hydroxyalkylated cyclodextrins, C1-C3 monohydric alcohols, C2-C3 dihydric alcohols, C3-C6 trihydric alcohols, polyalkylene glycols, γ-lactones, polyvinyl pyrrolidone, chlorogenic acids, alkyl sulfates, and salts thereof,
[0227]
[0228] In formula (1), a is greater than or equal to 0.01 and less than or equal to 0.7, a+b is 1, n is an integer greater than or equal to 25 and less than or equal to 25000, the arrangement of each disaccharide structural unit is optionally random or block-like, and in each disaccharide structural unit, R is independently a carboxyl group or a carboxylate group.
[0229]
[24] The method according to
[23] , wherein the component (A) is selected from the group consisting of a nonionic surfactant, a hydroxyalkylated cyclodextrin, a C1-C3 monohydric alcohol and a polyalkylene glycol.
[0230]
[25] The method according to
[23] or
[24] above, wherein the polyalkylene glycol is polyethylene glycol.
[0231]
[26] The method according to
[25] above, wherein the weight average molecular weight of the polyethylene glycol is 200 or more and 6000 or less.
[0232]
[27] A method according to any one of
[23] to
[26] , wherein the component (A) is added to a final concentration of 0.01 w / v% to 60 w / v%, 0.01 w / v% to 30 wt%, 1 w / v% to 15 w / v%, or 2 w / v% to less than 10 w / v%.
[0233]
[28] The method according to any one of
[23] to
[27] , wherein the compound represented by the formula (1) and / or the component (A) comprises a buffer selected from the group consisting of a phosphate buffer, a citrate buffer and an acetate buffer.
[0234]
[29] The method according to any one of
[23] to
[28] above, wherein the method is carried out at a pH in the range of 4.5 to 7.0.
[0235]
[30] The method according to any one of
[23] to
[29] , wherein the compound represented by the formula (1) and the component (A) are allowed to coexist in an aqueous solvent.
[0236]
[31] A method for inhibiting the accumulation of diclofenac lactam in a pharmaceutical composition comprising a compound represented by the following formula (1), the method comprising the step of allowing the compound represented by the formula (1) and component (A) to coexist:
[0237] Component (A): at least one compound selected from the group consisting of nonionic surfactants, hydroxyalkylated cyclodextrins, C1-C3 monohydric alcohols, C2-C3 dihydric alcohols, C3-C6 trihydric alcohols, polyalkylene glycols, γ-lactones, polyvinyl pyrrolidone, chlorogenic acids, alkyl sulfates, and salts thereof,
[0238]
[0239] In formula (1), a is greater than or equal to 0.01 and less than or equal to 0.7, a+b is 1, n is an integer greater than or equal to 25 and less than or equal to 25000, the arrangement of each disaccharide structural unit is optionally random or block-like, and in each disaccharide structural unit, R is independently a carboxyl group or a carboxylate group.
[0240]
[32] The method according to
[31] , wherein the component (A) is selected from the group consisting of a nonionic surfactant, a hydroxyalkylated cyclodextrin, a C1-C3 monohydric alcohol and a polyalkylene glycol.
[0241]
[33] The method according to
[31] or
[32] above, wherein the polyalkylene glycol is polyethylene glycol.
[0242]
[34] The method according to
[33] above, wherein the weight average molecular weight of the polyethylene glycol is 200 or more and 6000 or less.
[0243]
[35] A method according to any one of
[31] to
[34] , wherein the pharmaceutical composition contains the compound represented by the formula (1) at a concentration of 0.01 w / v% to 80 w / v%, 0.1 w / v% to 10 w / v%, 0.5 w / v% to 5 w / v% or 1 w / v%.
[0244]
[36] A method according to any one of
[31] to
[35] , wherein the component (A) is added to a final concentration of 0.01 w / v% to 60 w / v%, 0.01 w / v% to 30 wt%, 1 w / v% to 15 w / v%, or 2 w / v% to less than 10 w / v%.
[0245]
[37] The method according to any one of
[31] to
[36] , wherein the compound represented by the formula (1) and / or the component (A) comprises a buffer selected from the group consisting of a phosphate buffer, a citrate buffer and an acetate buffer.
[0246]
[38] The method according to any one of
[31] to
[37] above, wherein the method is carried out at a pH in the range of 4.5 to 7.0.
[0247]
[39] The method according to any one of
[31] to
[38] above, wherein the pharmaceutical composition is an aqueous composition.
[0248]
[40] The method according to any one of
[31] to
[39] above, wherein the pharmaceutical composition is a pharmaceutical composition for treating joint diseases.
[0249]
[41] The pharmaceutical composition according to
[40] above, wherein the joint disease is osteoarthritis or rheumatoid arthritis.
[0250]
[42] Use of component (A) in the manufacture of a pharmaceutical composition containing a compound represented by the following formula (1), wherein the component (A) is at least one compound selected from the group consisting of a nonionic surfactant, a hydroxyalkylated cyclodextrin, a C1-C3 monohydric alcohol, a C2-C3 dihydric alcohol, a C3-C6 trihydric alcohol, a polyalkylene glycol, γ-lactone, polyvinyl pyrrolidone, chlorogenic acid, and an alkyl sulfate, and salts thereof, and the manufacture comprises a step of allowing the component (A) and the compound represented by the above formula (1) to coexist:
[0251]
[0252] In formula (1), a is greater than or equal to 0.01 and less than or equal to 0.7, a+b is 1, n is an integer greater than or equal to 25 and less than or equal to 25000, the arrangement of each disaccharide structural unit is optionally random or block-like, and in each disaccharide structural unit, R is independently a carboxyl group or a carboxylate group.
[0253]
[43] The use according to
[42] , wherein the component (A) is selected from the group consisting of nonionic surfactants, hydroxyalkylated cyclodextrins, C1-C3 monohydric alcohols and polyalkylene glycols.
[0254]
[44] The use according to
[42] or
[43] above, wherein the polyalkylene glycol is polyethylene glycol.
[0255]
[45] The use according to
[44] above, wherein the weight average molecular weight of the polyethylene glycol is greater than or equal to 200 and less than or equal to 6000.
[0256]
[46] The use according to any one of
[42] to
[45] , wherein the pharmaceutical composition contains the compound represented by the formula (1) at a concentration of 0.01 w / v% to 80 w / v%, 0.1 w / v% to 10 w / v%, 0.5 w / v% to 5 w / v% or 1 w / v%.
[0257]
[47] The application according to any one of
[42] to
[46] , wherein the component (A) is added at a final concentration of 0.01 w / v% to 60 w / v%, 0.01 w / v% to 30 wt%, 1 w / v% to 15 w / v%, or 2 w / v% to less than 10 w / v%.
[0258]
[48] The use according to any one of
[42] to
[47] above, wherein the pharmaceutical composition is a pharmaceutical composition for treating joint diseases.
[0259]
[49] The use according to
[48] , wherein the joint disease is osteoarthritis or rheumatoid arthritis.
[0260]
[50] A component (A) for treating human joint diseases, wherein the component (A) is at least one compound selected from the group consisting of nonionic surfactants, hydroxyalkylated cyclodextrins, C1-C3 monohydric alcohols, C2-C3 dihydric alcohols, C3-C6 trihydric alcohols, polyalkylene glycols, γ-lactones, polyvinyl pyrrolidone, chlorogenic acids, alkyl sulfates, and salts thereof, wherein the component (A) is used together with a compound represented by the following formula (1) as a constituent component of a pharmaceutical composition for treating joint diseases, wherein the component (A):
[0261]
[0262] In formula (1), a is greater than or equal to 0.01 and less than or equal to 0.7, a+b is 1, n is an integer greater than or equal to 25 and less than or equal to 25000, the arrangement of each disaccharide structural unit is optionally random or block-like, and in each disaccharide structural unit, R is independently a carboxyl group or a carboxylate group.
[0263]
[51] The component (A) according to
[50] , wherein the component (A) is selected from the group consisting of a nonionic surfactant, a hydroxyalkylated cyclodextrin, a C1-C3 monohydric alcohol and a polyalkylene glycol.
[0264]
[52] The component (A) according to
[50] or
[51] above, wherein the polyalkylene glycol is polyethylene glycol.
[0265]
[53] The component (A) according to
[52] above, wherein the weight average molecular weight of the polyethylene glycol is 200 or more and 6,000 or less.
[0266]
[54] Component (A) according to any one of
[50] to
[53] above, wherein the final concentration of the compound represented by the formula (1) in the pharmaceutical composition is 0.01 w / v% to 80 w / v%, 0.1 w / v% to 10 w / v%, 0.5 w / v% to 5 w / v% or 1 w / v%.
[0267]
[55] The component (A) according to any one of
[50] to
[54] , wherein the final concentration of the component (A) in the pharmaceutical composition is 0.01 w / v% to 60 w / v%, 0.01 w / v% to 30 wt%, 1 w / v% to 15 w / v%, or 2 w / v% to less than 10 w / v%.
[0268]
[56] The component (A) according to any one of
[50] to
[55] , wherein the joint disease is osteoarthritis or rheumatoid arthritis.
[0269]
[57] A method for treating a human joint disease, comprising the step of administering a pharmaceutical composition to a joint of a patient with a joint disease, wherein the pharmaceutical composition comprises an effective amount of a compound represented by the following formula (1) and a component (A), wherein the component (A) is at least one compound selected from the group consisting of a nonionic surfactant, a hydroxyalkylated cyclodextrin, a C1-C3 monohydric alcohol, a C2-C3 dihydric alcohol, a C3-C6 trihydric alcohol, a polyalkylene glycol, a γ-lactone, a polyvinyl pyrrolidone, chlorogenic acids, and alkyl sulfates, and salts thereof:
[0270]
[0271] In formula (1), a is greater than or equal to 0.01 and less than or equal to 0.7, a+b is 1, n is an integer greater than or equal to 25 and less than or equal to 25000, the arrangement of each disaccharide structural unit is optionally random or block-like, and in each disaccharide structural unit, R is independently a carboxyl group or a carboxylate group.
[0272]
[58] The method according to
[57] above, wherein the component (A) is selected from the group consisting of a nonionic surfactant, a hydroxyalkylated cyclodextrin, a C1-C3 monohydric alcohol and a polyalkylene glycol.
[0273]
[59] The method according to
[57] or
[58] above, wherein the polyalkylene glycol is polyethylene glycol.
[0274]
[60] The method according to
[59] above, wherein the weight average molecular weight of the polyethylene glycol is 200 or more and 6000 or less.
[0275]
[61] The method according to any one of
[57] to
[60] , wherein the concentration of the compound represented by the formula (1) in the pharmaceutical composition is 0.01 w / v% to 80 w / v%, 0.1 w / v% to 10 w / v%, 0.5 w / v% to 5 w / v% or 1 w / v%.
[0276]
[62] A method according to any one of
[57] to
[61] , wherein the concentration of the component (A) in the pharmaceutical composition is 0.01 w / v% to 60 w / v%, 0.01 w / v% to 30 wt%, 1 w / v% to 15 w / v%, or 2 w / v% to less than 10 w / v%.
[0277]
[63] The method according to any one of
[57] to
[62] above, wherein the joint disease is osteoarthritis or rheumatoid arthritis.
[0278] Example
[0279] Hereinafter, preferred embodiments of the present invention will be described in more detail using examples, but the present invention is not limited to the following examples at all.
[0280] <Synthesis example>
[0281] According to the method described in Examples of International Publication No. 2005 / 066214, a hyaluronic acid derivative (compound represented by formula (1)) (a: 0.18, n: 2,000, mass average molecular weight of hyaluronic acid: 800,000) was synthesized.
[0282] More specifically, it was synthesized by the following method.
[0283] 2-Bromoethylamine hydrobromide 2.155g (10.5mmol) was dissolved in dichloromethane 20mL, triethylamine 1.463mL (10.5mmol) was added under ice-cold, and then dichloromethane solution 5mL of di-tert-butyl dicarbonate (Boc2O) 2.299g (10.5mmol) was added and stirred. After stirring at room temperature for 90 minutes, ethyl acetate was added, and liquid separation and washing were performed with 5 wt% citric acid aqueous solution, water, and saturated brine in sequence. After dehydration with sodium sulfate, the solvent was distilled off under reduced pressure to obtain Boc-aminoethyl bromide.
[0284] Ice-cool 5 mL of dimethylformamide (DMF) solution of 2.287 g (10.2 mmol) of Boc-aminoethyl bromide obtained above, add 6 mL of DMF solution of 3.255 g (10.2 mmol) of diclofenac sodium, and stir overnight at room temperature. Stir at 60°C for 11 hours and stir overnight at room temperature. Add ethyl acetate, and wash with 5 wt% sodium bicarbonate aqueous solution, water, and saturated brine in sequence. After dehydration with sodium sulfate, distill off the ethyl acetate under reduced pressure. Purify the residue by silica gel column chromatography (toluene: ethyl acetate = 20: 1 (v / v), 0.5 volume% triethylamine) to obtain Boc-aminoethanol-diclofenac.
[0285] 2.108 g (4.80 mmol) of Boc-aminoethanol-diclofenac obtained above was dissolved in 5 mL of dichloromethane, and 20 mL of 4M hydrochloric acid / ethyl acetate was added under ice cooling and stirred for 2.5 hours. Diethyl ether and hexane were added to precipitate, and the precipitate was dried under reduced pressure. Thus, aminoethanol-diclofenac hydrochloride was obtained. Structure utilization 1 Identification by H-NMR:
[0286] 1 H-NMR (500MHz, CDCl3) δ (ppm) = 3.18 (2H, t, NH2CH2CH2O-), 3.94 (2H, s, Ph-CH2-CO), 4.37 (2H, t, NH2CH2CH2O-), 6.47-7.31 (8H, m, Aromatic H, NH).
[0287] After dissolving 500 mg of hyaluronic acid (1.25 mmol / disaccharide unit) with a mass average molecular weight of 800,000 in 56.3 mL of water / 56.3 mL of dioxane, hydroxysuccinimide (1 mmol) / 0.5 mL of water, water-soluble carbodiimide hydrochloride (WSCI·HCl) (0.5 mmol) / 0.5 mL of water, and the aminoethanol-diclofenac hydrochloride (0.5 mmol) / (water: dioxane = 1:1 (v / v), 5 mL) obtained above were added in sequence, and stirred for a day and night. 7.5 mL of 5 wt% sodium bicarbonate aqueous solution was added to the reaction solution, and stirred for about 4 hours. After adding 215 μL of 50% (v / v) acetic acid aqueous solution to the reaction solution for neutralization, 2.5 g of sodium chloride was added and stirred. 400 mL of ethanol was added to make a precipitation, and the precipitate was washed twice with 85% (v / v) ethanol aqueous solution, washed twice with ethanol, and washed twice with diethyl ether, and dried under reduced pressure at room temperature overnight to obtain a hyaluronic acid derivative (sodium salt) (compound represented by formula (1)). The introduction rate of diclofenac measured by spectrophotometer was 18 mol%.
[0288] Furthermore, according to the above-mentioned synthesis example, a dried product of a hyaluronic acid derivative (sodium salt) having an introduction rate of 18 mol % was prepared.
[0289] <Preparation of test samples>
[0290] Preparation of phosphate buffer
[0291] A phosphate buffer solution was prepared by mixing a sodium dihydrogen phosphate aqueous solution having a phosphate concentration of 75 mM and a sodium hydrogen phosphate aqueous solution having a phosphate concentration of 75 mM at a ratio (volume ratio) of 17:11. The pH of the prepared phosphate buffer solution was 6.5.
[0292] Preparation of citrate buffer
[0293] A citric acid buffer solution was prepared by mixing a citric acid aqueous solution having a citric acid concentration of 15 mM and a trisodium citrate aqueous solution having a citric acid concentration of 15 mM at a ratio (volume ratio) of 27:37. The pH of the prepared citric acid buffer solution was 5.1.
[0294] Preparation of acetate buffer
[0295] An acetic acid buffer solution was prepared by mixing an acetic acid aqueous solution having an acetic acid concentration of 15 mM and an acetic acid sodium acetate aqueous solution having an acetic acid concentration of 15 mM at a ratio of 1:3 (volume ratio). The pH of the prepared acetic acid buffer solution was 5.1. In addition, an acetic acid buffer solution having a pH of 5.1 was prepared at a concentration of 45 mM acetic acid using the same method.
[0296] Preparation of 1.5 wt% hyaluronic acid derivative solution
[0297] 1.5 g of the hyaluronic acid derivative of the above synthesis example and 98.5 g of the various buffer solutions prepared above were mixed, and stirred in a 70° C. hot water bath for 2 hours to prepare a 1.5 wt % hyaluronic acid derivative solution.
[0298] Preparation of aqueous solutions of various additives
[0299] The aqueous solution of the additive component to be added to the hyaluronic acid derivative solution was prepared using various additive components and WFI so as to have a concentration (weight %) three times the final concentration.
[0300] Preparation of test samples
[0301] 2.0 g of the 1.5 wt % hyaluronic acid derivative solution prepared above was mixed with 1.0 g of the aforementioned additive aqueous solution to prepare a test sample (final concentration of hyaluronic acid derivative: 1.0 wt %). In addition, 1.0 g of WFI was mixed instead of 1.0 g of the additive aqueous solution to prepare a control solution not containing the aforementioned additive.
[0302] Example 1 Effect of Additives on the Accumulation of Diclofenac Components
[0303] The test samples prepared above containing various buffers (50 mM phosphate buffer, 10 mM citrate buffer, 10 mM acetate buffer, or 30 mM acetate buffer) were subjected to a preservation test.
[0304] After the test sample was stored in a thermostatic chamber at 60° C. for one week, the accumulated amounts of diclofenac and diclofenac lactam were measured by HPLC.
[0305] The amount of diclofenac and the amount of diclofenac lactam were calculated as relative values when the amount of diclofenac and the amount of diclofenac lactam present in a control solution (1 wt % hyaluronic acid derivative solution) stored at 60° C. for one week were set to 1.
[0306] More specific steps for saving the experiment are as follows.
[0307] <Save Test>
[0308] The prepared various test samples were filled into screw vials (AS ONE, Cat No.: 3-1599-01) and left to stand for 1 week at 60° C. The amount of diclofenac and diclofenac lactam present in the solution after standing was quantitatively analyzed by HPLC.
[0309] The HPLC conditions were as follows.
[0310] Column: TSGgel ODS-100Z (4.6mm×150mm)
[0311] Flow rate: 1mL / min
[0312] Temperature: 35℃
[0313] Gradient: acetonitrile (B) / 20 mM sodium phosphate (A)
[0314] B concentration. (mL / min)
[0315] 0.40(0 minutes)-0.80(30 minutes)
[0316] 0.80(33 minutes)-0.40(35 minutes)
[0317] The elution times of diclofenac and diclofenac lactam were determined in advance by measurement using standard substances.
[0318] It should be noted that storage at 60°C for one week is equivalent to storage at 25°C for one year.
[0319] (1-1) Storage test using 50 mM phosphate buffer (pH 6.5)
[0320] As the additives, L-arginine hydrochloride (final concentration in the test sample: 3 wt%), L-methionine, L-lysine hydrochloride (3 wt%), α-cyclodextrin, β-cyclodextrin, γ-cyclodextrin, allyloxy-1,2-propanediol, sodium edetate (3 wt%), glycine, diglycerol, sodium thioglycolate (3 wt%), tetrakis(4-carboxyphenyl)porphyrin (1.5 wt%), nicotinamide, butylated hydroxyanisole, phlorizin hydrate (1.5 wt%), benzyl alcohol, boric acid, polyvinyl alcohol (1.5 wt%), D-erythrolactone, D-glucuraldehyde, PEG200, PEG4000, sodium isoascorbate (3 wt%), and glycerol were used. The additives whose concentrations were not described were all used at a final concentration of 5 wt%.
[0321] <Results>
[0322] When L-arginine hydrochloride, L-methionine, L-lysine hydrochloride, α-cyclodextrin, β-cyclodextrin, γ-cyclodextrin, allyloxy-1,2-propanediol, sodium edetate, glycine, diglycerol, sodium thioglycolate, tetrakis(4-carboxyphenyl)porphyrin, nicotinamide, butylhydroxyanisole, phlorizin hydrate, benzyl alcohol, boric acid, and polyvinyl alcohol were used as additives, the amount of diclofenac lactam (relative value) exceeded 1 in all cases. That is, compared with the control without the additive, an increase in the amount of diclofenac lactam produced was observed, and the production of diclofenac lactam was promoted. When these additives were used, the amount of diclofenac (relative value) exceeded 1 in all cases except for the case of butylhydroxyanisole. The amount of diclofenac (relative value) in the case of butylhydroxyanisole was 0.99, and almost no effect on the production of diclofenac as an additive was observed.
[0323] On the other hand, when D-erythrolactone, D-glucuraldehyde, PEG200, PEG4000, sodium isoascorbate, and glycerol were used as the additives, the amount of diclofenac lactam (relative value) was less than 1. That is, compared with the control without using the additive, a decrease in the amount of diclofenac lactam produced was observed, and the production of diclofenac lactam was suppressed (Table 1).
[0324] Since the formation of diclofenac lactam, which is actually inactive as a COX-2 inhibitor, is inhibited, it is clear that D-erythrolactone, D-glucurone, PEG200, PEG4000, sodium isoascorbate, and glycerol can inhibit the accumulation of diclofenac lactam. Furthermore, among these, it can be seen that the amount of diclofenac (relative value) of D-erythrolactone and sodium isoascorbate is less than 1, and the accumulation of diclofenac is also inhibited.
[0325] [Table 1]
[0326]
[0327] *Lac amount; relative value of diclofenac lactam amount
[0328] **Dic amount; relative value of diclofenac amount
[0329] (1-2) Storage test using 10 mM citric acid buffer (pH 5.1)
[0330] As additives, creatinine (1 wt%), sodium deoxycholate (5 wt%), 1,2,3-butanetriol (5 wt%), PEG400 (6.3 wt% or 16.5 wt%), PEG600 (10 wt%), PEG4000 (10 wt%), PEG6000 (10 wt%), SDS (5 wt%), TritonX-100 (5 wt%), ethanol (26 wt%), octyl glucoside (5 wt%), glucuronolactone (0.1 wt%), chlorogenic acid (0.1 wt%), propylene glycol (10 wt%), polysorbate 20 (5 wt%), and polyvinylpyrrolidone (5 wt%) were used.
[0331] Similarly, as additive components, two-component systems of PEG3350 (10.6 wt %) and polysorbate 80 (3 wt %), and PEG3350 (6.0 wt %) and hydroxypropyl-β-cyclodextrin (10 wt %), or three-component systems of PEG3350 (5.5 wt %), polysorbate 80 (1 wt %) and hydroxypropyl-β-cyclodextrin (10 wt %) were used.
[0332] <Results>
[0333] When creatinine and sodium deoxycholate were used as additives, the diclofenac lactam amount (relative value) exceeded 1. That is, compared with the control without the additive, an increase in the amount of diclofenac lactam produced was observed, and the production of diclofenac lactam was promoted. When these additives were used, the diclofenac amount (relative value) also exceeded 1.
[0334] On the other hand, when 1,2,3-butanetriol, PEG400, PEG600, PEG4000, PEG6000, SDS, TritonX-100, ethanol, octyl glucoside, glucuronolactone, chlorogenic acid, propylene glycol, polysorbate 20, and polyvinylpyrrolidone were used as additives, the amount of diclofenac lactam (relative value) was less than 1. That is, compared with the control without the additive, a decrease in the amount of diclofenac lactam produced was observed, and the production of diclofenac lactam was suppressed (Table 2). Table 2 also shows the properties of the solution after storage. The solution properties are colorless and clear in most cases. Even if there is coloration, it is only to the extent of yellowing, and even if it is not clear, it is only to the extent of turbidity. In addition, when the above-mentioned two-component system or three-component system is used, the amount of diclofenac lactam (relative value) and the amount of diclofenac (relative value) are both less than 1. In addition, the solutions of these two-component and three-component systems were all colorless and clear (Table 3).
[0335] Since the production of diclofenac lactam, which is substantially inactive as a COX-2 inhibitor, is suppressed, it is clear that 1,2,3-butanetriol, PEG400, PEG600, PEG4000, PEG6000, SDS, TritonX-100, ethanol, octyl glucoside, glucuronolactone, chlorogenic acid, propylene glycol, polysorbate 20, and polyvinylpyrrolidone can be used as diclofenac lactam accumulation inhibitors. Moreover, when these are used, the amount of diclofenac (relative value) is also less than 1, which shows that the accumulation of diclofenac is also suppressed.
[0336] [Table 2]
[0337]
[0338] *Lac amount; relative value of diclofenac lactam amount
[0339] **Dic amount; relative value of diclofenac amount
[0340] [Table 3]
[0341]
[0342] *Lac amount; relative value of diclofenac lactam amount
[0343] **Dic amount; relative value of diclofenac amount
[0344] (1-3) Storage test using 30 mM acetate buffer (pH 5.1)
[0345] As additives, propyl gallate (1.5 wt%), lactic anhydride (1.5 wt%), hydroxypropylcellulose (1.5 wt%), starch (1.5 wt%), dextran (5 wt%), sucrose (5 wt%), saccharin sodium dihydrate (5 wt%), glycine (5 wt%), sodium aspartate (1.5 wt%), L-leucine (1.5 wt%), L-phenylalanine (5 wt%), L-serine (5 wt%), D-mannitol (1.5 wt%), D-sorbitol (5 wt%), hydroxypropyl-β-cyclodextrin (3 wt%, 5 wt%, 10 wt% or 15 wt%), and ethanol (5 wt%, 10 wt%, 20 wt% or 26.3 wt%) were used.
[0346] <Results>
[0347] When propyl gallate, lactic anhydride, hydroxypropylcellulose, starch, dextran, sucrose, saccharin sodium dihydrate, glycine, sodium aspartate, L-leucine, L-phenylalanine, L-serine, D-mannitol, and D-sorbitol were used as additives, the diclofenac lactam amount (relative value) exceeded 1 in all cases. That is, compared with the control without the additive, an increase in the amount of diclofenac lactam produced was observed, and the production of diclofenac lactam was promoted. When these additives were used, the diclofenac amount (relative value) also exceeded 1 in all cases.
[0348] On the other hand, when hydroxypropyl-β-cyclodextrin (HP-β-CD) and ethanol were used as the added components, the amount of diclofenac lactam (relative value) was less than 1. That is, compared with the control without using the added component, a decrease in the amount of diclofenac lactam accumulation was observed, and the accumulation of diclofenac lactam was suppressed (Table 4).
[0349] Since hydroxypropyl-β-cyclodextrin and ethanol can be used as diclofenac lactam accumulation inhibitors because they inhibit the production of diclofenac lactam, which is substantially inactive, as COX-2 inhibitors. Moreover, when these are used, the diclofenac amount (relative value) is also less than 1, which shows that the accumulation of diclofenac is also inhibited.
[0350] [Table 4]
[0351]
[0352] *Lac amount; relative value of diclofenac lactam amount
[0353] **Dic amount; relative value of diclofenac amount
[0354] (1-4) Storage test using 10 mM acetate buffer (pH 5.1)
[0355] As additives, hydroxyethyl-β-cyclodextrin (5 wt%), PEG400 (7.5 wt%), PEG4000 (5 wt% or 15 wt%), ethanol (10 wt%), octylglucoside (5 wt%), polysorbate 80 (5 wt% or 10 wt%), and polyvinylpyrrolidone (5 wt%) were used.
[0356] <Results>
[0357] When hydroxyethyl-β-cyclodextrin (HP-β-CD), PEG400, PEG4000, ethanol, octyl glucoside, polysorbate 80, and polyvinyl pyrrolidone were used as the additive, the amount of diclofenac lactam (relative value) was less than 1. That is, compared with the control without using the additive, a decrease in the amount of diclofenac lactam accumulation was observed, and the accumulation of diclofenac lactam was suppressed (Table 5).
[0358] Since the production of diclofenac lactam, which is substantially inactive as a COX-2 inhibitor, is suppressed, it is clear that hydroxypropyl-β-cyclodextrin, PEG400, PEG4000, ethanol, octylglucoside, polysorbate 80, and polyvinylpyrrolidone can be used as an accumulation inhibitor of diclofenac lactam. Furthermore, when these are used, the amount of diclofenac (relative value) is also less than 1, which shows that the accumulation of diclofenac is also suppressed.
[0359] [Table 5]
[0360]
[0361] *Lac amount; relative value of diclofenac lactam amount
[0362] **Dic amount; relative value of diclofenac amount
[0363] <Conclusion>
[0364] This example confirmed that polysorbate 20, polysorbate 80, Triton X-100, octyl glucoside, hydroxyethyl-β-cyclodextrin, hydroxypropyl-β-cyclodextrin, ethanol, glycerol, 1,2,3-butanetriol, D-glucurone, PEG200, PEG400, PEG600, PEG4000, PEG6000, D-erythrolactone, sodium isoascorbate, glucuronolactone, polyvinyl pyrrolidone, chlorogenic acid, SDS, and propylene glycol have the effect of inhibiting the accumulation of diclofenac lactam.
[0365] Therefore, nonionic surfactants such as polysorbate 20, polysorbate 80, Triton X-100, and octylglucoside; hydroxyalkylated cyclodextrins such as hydroxyethyl-β-cyclodextrin and hydroxypropyl-β-cyclodextrin; C1-C3 monohydric alcohols such as ethanol; C2-C3 dihydric alcohols such as propylene glycol; C3-C6 trihydric alcohols such as glycerol, 1,2,3-butanetriol, and D-glucurone; polyalkylene glycols such as PEG200, PEG400, PEG600, PEG4000, and PEG6000; γ-lactones such as D-erythrolactone, sodium isoascorbate, and glucuronolactone; polyvinyl pyrrolidone; chlorogenic acids such as chlorogenic acid and alkyl sulfates such as SDS can be used as inhibitors of the production of diclofenac lactam from hyaluronic acid derivatives; in addition, they can be used as inhibitors of the accumulation of diclofenac lactam in pharmaceutical compositions containing hyaluronic acid derivatives. Moreover, pharmaceutically acceptable salts thereof can also be used in the same manner.
[0366] Example 2 Evaluation of Filterability of Aqueous Compositions
[0367] The filtration of aqueous compositions containing hyaluronic acid derivatives was studied for hydroxypropyl-β-cyclodextrin (HP-β-CD), ethanol, PEG400, and PEG4000.
[0368] <Preparation of test samples>
[0369] Preparation of 1.5 wt% hyaluronic acid derivative solution
[0370] The hyaluronic acid derivative prepared in the above and the 15 mM acetic acid buffer (pH 5.1) prepared in the above were mixed, stirred, and then allowed to stand for defoaming, thereby preparing a 1.5 wt % hyaluronic acid derivative solution.
[0371] Preparation of test samples
[0372] 150.0 g of the 1.5 wt % hyaluronic acid derivative solution prepared above and 75.0 g of the aqueous solution of the additional component were mixed to prepare a test sample (final concentration of the hyaluronic acid derivative: 1.0 wt %).
[0373] In addition, a control solution was prepared by mixing 75.0 g of WFI instead of the added component aqueous solution.
[0374] <Test method for filterability>
[0375] A polyvinylidene fluoride (PVDF) membrane (47 mm diameter, effective filtration area: 13.8 cm) with a pore size of 0.22 μm was installed. 2200 mL of the test sample prepared above was added to a stainless steel pressure filter holder (manufactured by Merck) and pressurized at 0.6 MPa at 70°C. The amount of liquid passing through the filter was weighed every 30 seconds, and the maximum processing volume (V) was calculated based on the relationship between the elapsed time and the total filtration volume. max ).
[0376] <Results>
[0377] When using additives, the maximum processing capacity (V max ) are 1.0g / cm 2 In particular, the maximum treatment volume (V max ) is a high value.
[0378] [Table 6]
[0379]
[0380] <Conclusion>
[0381] When filtering, if the filtration is stopped before the flow rate reaches 1 / 10 of the initial flow rate, the filter cannot be used effectively. If it is used again, the filtration time will be longer, which is not preferred in terms of work efficiency. max The V90 value calculated by multiplying the value by 0.68 (the reduction rate of the filter processing capacity at the time when the flow rate reaches 1 / 10 of the initial flow rate is set to 68%) is equivalent to the processing volume until the flow rate reaches 1 / 10 of the initial flow rate. It is known that the V90 value is an empirically preferred value for evaluating the filtration capacity (if necessary, refer to Kobayashi Kohiko, "V max Selection and Optimization Methods of Test Filters", Bioprocess Technical Sheet Basic Technology No. 2, Millipore, Japan, August 1997). The maximum processing capacity (V max ) is 1.0g / cm 2 The above aqueous composition has a high V90 value, so it can be said that the filterability is excellent. That is, such an aqueous composition is suitable for industrial-scale mass production because it is not easy to be clogged during filtration, and the frequency of filter replacement and cleaning is reduced. Therefore, even when it is provided in the form of a pharmaceutical composition, heat sterilization is not required. Therefore, it can be provided in the form of a composition in which the accumulation of diclofenac components, especially the accumulation of diclofenac lactam, is suppressed.
[0382] Example 3 Preparation of pharmaceutical composition
[0383] Component (A) is used together with a hyaluronic acid derivative to prepare a pharmaceutical composition. As an example, the preparation of a pharmaceutical composition for injection containing a hyaluronic acid derivative, PEG400, and a citric acid buffer solution is shown.
[0384] (Step 1) Predetermined amounts of citric acid hydrate, disodium citrate hydrate, and PEG400 are dissolved in WFI.
[0385] (Step 2) A predetermined amount of a hyaluronic acid derivative (introduction rate: 18 mol%) is dissolved in the solution of step 1. The dissolved solution is heated to 70°C and degassed by heating under reduced pressure.
[0386] (Step 3) The solution in step 2 was sterilized by filtration using a filter having a pore size of 0.22 μm.
[0387] (Step 4) The solution obtained in Step 3 was heated at 70°C for deaeration and then cooled to 10°C.
[0388] (Step 5) A predetermined amount is filled into a syringe under sterile conditions.
[0389] Through the above (step 1) to (step 5), a sterilized pharmaceutical composition containing a hyaluronic acid derivative, PEG400 and a citric acid buffer solution can be prepared. Here, the concentration of each component can be exemplified by hyaluronic acid derivative; 0.5-5w / v%, PEG400; 3-30w / v%, and citric acid buffer solution; 3-30mM (calculated as citric acid), but the concentration of each component in the pharmaceutical composition is not limited to the aforementioned ranges.
[0390] Industrial Applicability
[0391] The present invention provides, for example, a composition having excellent stability in which the accumulation of diclofenac lactam, a physiologically inactive component, is suppressed, and the composition has a significant effect on improving joint diseases in human joint disease patients (particularly, chronic joint disease patients), and therefore has industrial applicability in the pharmaceutical industry and the like.
[0392] The present invention has been described in relation to specific examples and various implementations, but it is readily apparent to those skilled in the art that most of the implementations described in this specification can be modified and applied without departing from the spirit and scope of the present invention.
[0393] This application claims priority based on Japanese Patent Application No. 2018-215867 filed with the Japan Patent Office on November 16, 2018, the entire contents of which are incorporated herein by reference.
Claims
1. An aqueous composition comprising a compound as shown in (1) below and a filterability improving agent, and having a maximum treatment capacity V max 1.0g / cm 2 above, The filterability improving agent is selected from the group consisting of polyethylene glycol, ethanol, hydroxyalkylated cyclodextrin and their salts, wherein The maximum processing capacity V max The following value is obtained by filtering the aqueous composition at a liquid temperature of 70° C. using a polyvinylidene fluoride filter membrane having a pore size of 0.22 μm under a pressure of 0.6 MPa, measuring the total filtration volume per unit effective filtration area every 30 seconds until the flow rate becomes less than 1 / 10 of the flow rate at the start of filtration, and applying the measured value obtained in this way to the value derived in the following formulas A and B: Formula A: t / V=at+b Formula B: In max =1 / a In the above formulas A and B, t is the filtration time in minutes, and V is the total filtration volume per unit effective filtration area in g / cm 2 , a is the slope of formula A, b is the intercept of formula A: In formula (1), a is greater than or equal to 0.01 and less than or equal to 0.7, a+b is 1, n is an integer greater than or equal to 25 and less than or equal to 25000, the arrangement of each disaccharide structural unit is optionally random or block-like, and in each disaccharide structural unit, R is independently a carboxyl group or a carboxylate group.
2. The aqueous composition according to claim 1, wherein The relative amount of diclofenac lactam measured under the following conditions is less than 0.9: A test composition in which the compound represented by formula (1) and a filterability improver coexisted, and a control composition having the same composition as above except that the filterability improver was not contained, were stored in a thermostatic chamber at 60° C. for 1 week, and then the amounts of diclofenac lactam accumulated in the test composition and the control composition were measured by high performance liquid chromatography, and the relative amount of diclofenac lactam accumulated in the test composition when the amount of diclofenac lactam accumulated in the control composition was set to 1 was calculated.
3. The aqueous composition according to claim 1, wherein The relative amount of diclofenac measured under the following conditions is less than 1: A test composition in which the compound represented by formula (1) and a filterability improver coexisted, and a control composition having the same composition as above except that the filterability improver was not contained, were stored in a thermostatic chamber at 60° C. for 1 week, and then the amount of diclofenac accumulated in the test composition and the control composition was measured by high performance liquid chromatography, and the relative amount of diclofenac accumulated in the test composition when the amount of diclofenac accumulated in the control composition was set to 1 was calculated. 4 . The aqueous composition according to claim 1 , which is used for treating joint diseases.
5. The aqueous composition according to any one of claims 1 to 3, wherein The compound represented by formula (1) is contained at a concentration of 0.01 w / v% or more and 80 w / v% or less. 6 . A kit comprising a syringe in which a syringe barrel is filled with the aqueous composition according to claim 1 .
7. A kit comprising a vial and a syringe, wherein the vial comprises the aqueous composition according to any one of claims 1 to 5.
8. Use of the aqueous composition according to any one of claims 1 to 5 for producing a therapeutic agent for human joint diseases.
9. A pharmaceutical composition comprising a compound represented by the following formula (1) and component (A): Component (A): at least one compound selected from the group consisting of nonionic surfactants, hydroxyalkylated cyclodextrins, C1-C3 monohydric alcohols, C2-C3 dihydric alcohols, C3-C6 trihydric alcohols, polyalkylene glycols, γ-lactones, polyvinyl pyrrolidone, chlorogenic acids, alkyl sulfates, and salts thereof, In formula (1), a is greater than or equal to 0.01 and less than or equal to 0.7, a+b is 1, n is an integer greater than or equal to 25 and less than or equal to 25000, the arrangement of each disaccharide structural unit is optionally random or block-like, and in each disaccharide structural unit, R is independently a carboxyl group or a carboxylate group.
10. The pharmaceutical composition according to claim 9, wherein The component (A) is selected from the group consisting of nonionic surfactants, hydroxyalkylated cyclodextrins, C1-C3 monohydric alcohols and polyalkylene glycols.
11. The pharmaceutical composition according to claim 9 or 10, wherein The polyalkylene glycol is polyethylene glycol.
12. The pharmaceutical composition according to claim 11, wherein The weight average molecular weight of polyethylene glycol is 200 or more and 6000 or less.
13. The pharmaceutical composition according to claim 9 or 10, wherein The final concentration of the component (A) is 0.01 to 30 wt %.
14. The pharmaceutical composition according to claim 9 or 10, further comprising a buffer selected from the group consisting of a phosphate buffer, a citrate buffer and an acetate buffer.
15. The pharmaceutical composition according to claim 9 or 10, wherein The pH is 4.5-7.
0.
16. The pharmaceutical composition according to claim 9 or 10, which is an aqueous composition.
17. The pharmaceutical composition according to claim 9 or 10, which is a pharmaceutical composition for treating joint diseases.
18. The pharmaceutical composition according to claim 17, wherein The joint disease is osteoarthritis or rheumatoid arthritis.
19. A kit comprising a syringe in which a syringe barrel is filled with the pharmaceutical composition according to any one of claims 9 to 18.
20. A kit comprising a vial and a syringe, wherein the vial comprises the pharmaceutical composition according to any one of claims 9 to 18.
21. A method for producing a pharmaceutical composition, the pharmaceutical composition comprising a compound represented by the following formula (1), the method comprising the step of allowing the compound represented by the following formula (1) to coexist with component (A): Component (A): at least one compound selected from the group consisting of nonionic surfactants, hydroxyalkylated cyclodextrins, C1-C3 monohydric alcohols, C2-C3 dihydric alcohols, C3-C6 trihydric alcohols, polyalkylene glycols, γ-lactones, polyvinyl pyrrolidone, chlorogenic acids, alkyl sulfates, and salts thereof, In formula (1), a is greater than or equal to 0.01 and less than or equal to 0.7, a+b is 1, n is an integer greater than or equal to 25 and less than or equal to 25000, the arrangement of each disaccharide structural unit is optionally random or block-like, and in each disaccharide structural unit, R is independently a carboxyl group or a carboxylate group.
22. The method according to claim 21, wherein: The component (A) is selected from the group consisting of nonionic surfactants, hydroxyalkylated cyclodextrins, C1-C3 monohydric alcohols and polyalkylene glycols.
23. The method according to claim 21 or 22, wherein: The polyalkylene glycol is polyethylene glycol.
24. The method according to claim 23, wherein: The weight average molecular weight of polyethylene glycol is 200 or more and 6000 or less.
25. The method according to claim 21 or 22, wherein: The component (A) is added at a final concentration of 0.01 to 30 wt%.
26. The method according to claim 21 or 22, wherein: The compound represented by formula (1) and / or component (A) contains a buffer selected from the group consisting of a phosphate buffer, a citrate buffer and an acetate buffer.
27. The method according to claim 21 or 22, wherein: The pH of the pharmaceutical composition is 4.5-7.
0.
28. The method according to claim 21 or 22, wherein: The pharmaceutical composition is an aqueous composition.
29. A method for inhibiting the formation of diclofenac lactam from a compound represented by the following formula (1), comprising the step of allowing the compound represented by the following formula (1) to coexist with component (A): Component (A): at least one compound selected from the group consisting of nonionic surfactants, hydroxyalkylated cyclodextrins, C1-C3 monohydric alcohols, C2-C3 dihydric alcohols, C3-C6 trihydric alcohols, polyalkylene glycols, γ-lactones, polyvinyl pyrrolidone, chlorogenic acids, alkyl sulfates, and salts thereof, In formula (1), a is greater than or equal to 0.01 and less than or equal to 0.7, a+b is 1, n is an integer greater than or equal to 25 and less than or equal to 25000, the arrangement of each disaccharide structural unit is optionally random or block-like, and in each disaccharide structural unit, R is independently a carboxyl group or a carboxylate group.
30. The method of claim 29, wherein: The component (A) is selected from the group consisting of nonionic surfactants, hydroxyalkylated cyclodextrins, C1-C3 monohydric alcohols and polyalkylene glycols.
31. The method according to claim 29 or 30, wherein: The polyalkylene glycol is polyethylene glycol.
32. The method according to claim 31, wherein: The weight average molecular weight of polyethylene glycol is 200 or more and 6000 or less.
33. The method according to claim 29 or 30, wherein: The component (A) is added at a final concentration of 0.01 to 30 wt%.
34. The method according to claim 29 or 30, wherein: The compound represented by the formula (1) and / or the component (A) comprises a buffer selected from the group consisting of a phosphate buffer, a citrate buffer and an acetate buffer.
35. The method according to claim 29 or 30, wherein: The reaction is carried out in the pH range of 4.5 to 7.
0.
36. The method according to claim 29 or 30, wherein: The compound represented by the formula (1) and the component (A) are allowed to coexist in an aqueous solvent.
37. Use of a compound represented by the following formula (1) in the manufacture of a therapeutic agent for human joint diseases, the therapeutic agent for joint diseases comprising an effective amount of the compound represented by the following formula (1) and a component (A), wherein the component (A) is at least one compound selected from the group consisting of a nonionic surfactant, a hydroxyalkylated cyclodextrin, a C1-C3 monohydric alcohol, a C2-C3 dihydric alcohol, a C3-C6 trihydric alcohol, a polyalkylene glycol, γ-lactone, polyvinyl pyrrolidone, chlorogenic acids and alkyl sulfates, and salts thereof, In formula (1), a is greater than or equal to 0.01 and less than or equal to 0.7, a+b is 1, n is an integer greater than or equal to 25 and less than or equal to 25000, the arrangement of each disaccharide structural unit is optionally random or block-like, and in each disaccharide structural unit, R is independently a carboxyl group or a carboxylate group.
38. The use according to claim 37, wherein: The component (A) is selected from the group consisting of nonionic surfactants, hydroxyalkylated cyclodextrins, C1-C3 monohydric alcohols and polyalkylene glycols.
39. The use according to claim 37 or 38, wherein: The polyalkylene glycol is polyethylene glycol.
40. The use according to claim 39, wherein: The weight average molecular weight of polyethylene glycol is 200 or more and 6000 or less.
41. The use according to claim 37 or 38, wherein: The concentration of the component (A) in the joint disease therapeutic agent is 0.01 to 30 wt %.
42. The use according to claim 37 or 38, wherein: The joint disease is osteoarthritis or rheumatoid arthritis.
43. An aqueous composition comprising a compound represented by the following formula (1) and a component that inhibits the accumulation and / or production of a diclofenac component, wherein the component that inhibits the accumulation and / or production of a diclofenac component is at least one compound selected from the group consisting of a nonionic surfactant, a hydroxyalkylated cyclodextrin, a C1-C3 monohydric alcohol, a C2-C3 dihydric alcohol, a C3-C6 trihydric alcohol, a polyalkylene glycol, γ-lactone, polyvinyl pyrrolidone, chlorogenic acids, alkyl sulfates, and salts thereof, wherein the relative amount of diclofenac lactam after storage in a thermostatic bath at 60° C. for one week is 0.9 or less, wherein: The relative amount is a value obtained by setting the amount of diclofenac lactam accumulated in a control composition, which is an aqueous composition identical to that of the control composition except that the component that inhibits the accumulation and / or production of diclofenac is not contained, as 1. In formula (1), a is greater than or equal to 0.01 and less than or equal to 0.7, a+b is 1, n is an integer greater than or equal to 25 and less than or equal to 25000, the arrangement of each disaccharide structural unit is optionally random or block-like, and in each disaccharide structural unit, R is independently a carboxyl group or a carboxylate group.
